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ABSTRACT
Functional Study of the Structural VP6 Protein of Bluetongue Virus
by
Emiko Hayama, Doctor of Philosophy
Utah State University, 1995
Major Professor: Dr. Joseph K. -K. Li
Department: Biology (Molecular Biology)
This study was undertaken to investigate the structure-function relationship of
VP6 protein of bluetongue virus (BTV) using molecular cloning techniques. VP6 is
present in small quantities in BTV and its enzymatic activity and role in the viral
replication cycle have not been studied. Since the availability of large amounts of
purified VP6 is essential for the analysis of VP6, a BTV -11 S3 gene was cloned into a
prokaryotic protein expression system. VP6 protein was expressed in large amounts and
purified to near homogeneity. A series of C-terminal and internal deletion mutants of S3
gene was constructed and the truncated VP6 proteins were expressed and putified. The
nucleic acid binding activities of the VP6 protein towards dsRNA, dsDNA, and ssRNA
were confirmed and a new ssDNA binding activity was also determined. The binding
activities of VP6 were concentration-dependent. The sites responsible for the binding
activities were mapped using the truncated proteins and synthetic sequence-specific
oligopeptides. Two domains of VP6 were responsible for the nucleic acid binding
activities and have been mapped within 28 amino acids near the middle and 11 residues
near the carboxyl terminus of VP6. The binding affinities of the middle domain of VP6
towards single-stranded and double-stranded nucleic acid were slightly different. Three
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synthetic oligopeptides corresponding to these domains exhibited concentrationdependent nucleic acid binding activities. Based on these results I suggest that synthetic
oligopeptides might be useful to screen nucleic acid binding activities and domains
responsible for these activities.
Expressed VP6 was used to produce polyclonal and monoclonal antibodies.
Oligoclonal antibodies were raised by synthetic oligopeptides. Ten epitopes of VP6 were
mapped and characterized. The amino acid sequences and sizes of six linear epitopes
identified by oligoclonal antibodies were determined, and their locations were mapped
and confirmed by deletion mutant analyses.

These linear epitopes were surface-

accessible except one. Based on these results I suggest that synthetic sequence-specific
oligopeptides could mimic major components of antigenic determinants. Four epitopes
recognized by four monoclonal antibodies were mapped and characterized. Three
determinants were surface-accessible and three were conformational epitopes. These
four determinants were distinct and different from the six linear epitopes determined
using oligoclonal antibodies.
(179 pages)
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CHAPTER I
LITERATURE REVIEW AND PROJECT OUTLINE
INTRODUCTION

Classification. Bluetongue virus (B1V) is a member of the Orbivirus genus in
the family Reoviridae (80) and the causal agent of bluetongue disease in domestic livestock
(sheep, goats, cattle, water-buffaloes, ca.11els, etc.) and wild ruminants (white-tailed deer,
elk, pronghorn antelope, etc.) (6, 38, 81, 126). Classification of B1V as a member of the
family Reoviridae is based upon the presence of a segmented, double-stranded (ds) RNA
genome as well as certain structural characteristics and a common replicative strategy. The
family Reoviridae includes six genera, Reovirus, Rotavirus, Cypovirus, Fijivirus, and
Phytoreovirus, and Orbivirus (136). B1V is the prototype virus of the genus Orbivirus.

The name Orbivirus had been proposed (3) and derived from the Latin "orbis" ("ring" or
"circle") reflecting the doughnut-shaped capsomers of virus particles when examined under
the electron microscope.

At least 24 different serotypes of B1V have been reported

worldwide, and five of them (BTV-2, -10,-11, -13, and -17) were isolated in the U.S.A.
(1, 36, 37).

Bluetongue disease. The records of bluetongue disease in sheep and cattle may
date back to the late 18th century (37). B1V is wide spread throughout many countries of
Mrica (South Mrica, Kenya, and Sudan), Asia (Israel, Pakistan, India, Japan, Papua New
Guinea, Malaysia, and Indonesia), Australia, Europe (Spain, Portugal, and Greece), and
the U.S.A. Its spread depends on the availability of suitable carrier, the biting midges of
the species Culicoides ( 118). Typical clinical signs of the bluetongue disease in sheep are
as follows: the first symptom is a high fever for 6 to 7 days (25), with an increased
respiratory rate occutTing early in the febrile response. By 7-10 days the tongue becomes
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severely affected and turns dark blue (37).

This cyanotic appearance gives the name

"bluetongue" to the disease. Most cases of BTV infection of sheep are subclinical or mild,
and the infected sheep generally recovers completely within a few weeks (118). However,
there have been a number of serious outbreaks; in Cyprus (1943-1944) a particularly
virulent strain killed 2,500 sheep, with a mortality rate of 70% (33); in Portugal and Spain
(1956) a strain of BTV-10 caused 179,000 deaths in sheep with a mortality of 75% (37).
Under average field conditions the mortality rate usually varies between 2 and 30% (25).
The direct losses due to mortality may be high, but the indirect losses may be of even
greater economic importance. For example, many months of nursing and feeding may be
required for the infected sheep to recover.

When the general systemic resistance is

invariably reduced, such animals easily fall prey to bacteria or chlamydia} infections, worm
infestations, blow-fly strike, or even to predators, suggesting wool growth is reduced and
retarded, and the breeding efficiency of infected sheep is also affected (25).

Bluetongue

was recognized as an "emerging disease of animals" (55) and has "explosive potential,
especially in countries like Australia where the sheep industry is of great economic
importance and bluetongue could raise havoc with an extremely susceptible sheep
population" (4: p. 11).
The first vaccine was developed by attenuating a strain of BTV (serotype-4)
through limited passages in sheep, and early attempts at the vaccination of animals against
the bluetongue infection were performed using either the attenuated viral strains or the
serum from sheep that had recovered from the sickness (37).

Currently, mixtures of

attenuated serotypes are used to vaccinate animals. In South Africa, sheep are vaccinated
with three pentavalent live attenuated virus vaccines at 3-week intervals. In the United
States, a modified live vaccine is only available for BTV -10 (130). The use of modified
live vaccine involves some risks, and has inherent problems, such as the inconvenience of
repetitive inoculation and pregnant ewes should not be immunized during the frrst half of
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pregnancy, during which their fetuses may develop teratogenic defects. Furthermore, there
is the possibility of genetic reassortment ( 131, 13 2, 140) and recombination between
attenuated and virulent strains, resulting in reversion to virulence, or even in the production
of new serotypes, which may be spread by the biting midges (148).

The inactivated

vaccine has not yet progressed to apply in large field trials, because of the requirement for a
relatively large innoculant dose necessary to obtain the level of protection afforded by live
vaccine.

Additionally, a hypersensitization has been reported in sheep previously

vaccinated with inactivated virus, when they are challenged with virulent virus. A subunit
vaccine developed through recombinant DNA technology, which would combine the
advantage of live viruses with the safety of inactivated products, may be the most
promising approach for novel vaccines against bluetongue (148).

Some attempts and

results by using subunit vaccine of BTV will be described later in this chapter.

Virion structure.

BTV is a non-enveloped virus (24). It resists lipid solvents

(141). Three morphologically distinct BTV particles, namely virions, cores, and subcore
particles, have been identified. The negatively stained bluetongue virion has an icosahedral
shape with a diameter of about 68-70 nm (107, 152).

The outer capsid layer differs

morphologically from that of reo viruses ( 117) and is the main distinguishing characteristic
for the members of the Orbivirus genus. The virion is converted to a core particle by the
removal of the outer capsid protein layer (VP2 and VP5); the diameter of the core particle is
reported to be 58 nm (110) or 54 nm (24). The core particle has 32 distinct morphological
units, or capsomers, in a circular configuration arranged in an icosahedral symmetry (24).
BTV core particles possess RNA-dependent RNA polymerase activity (107).

The core

particles can be further uncoated to subcore particles by removal of VP7 (67). The subcore
particles have a skeleton-like appearance with a hexagonally shaped outline and a diameter
of 40 nm (67). The subcore particles are stable only in very low salt buffers, have no
transcriptase activity, and consist of VP1, 3, 4, and 6, and the ds-RNA genome (67).
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Isolation, purification, and physicochemical properties.

BTV can be

purified from Freon or Triton X -100 extracted infected-cell homogenates, followed by
velocity sedimentation on preformed 20-40% sucrose density gradients (64, 107, 151 ).
Mertens et al. (110) described a method for purification of BTV, in which they used Tris
buffer containing 0.5% Triton X-100 following homogenization, the supernatant,
representing a cytoplasmic extract, were separated with discontinuous sucrose gradients.
The virus and cellular components were further treated with sodium deoxycholate,
followed by discontinuous sucrose gradient separation to prepare partially purified viruses.
They further treated the partial purified viruses with N-laurylsarcosinate and dithiothreitol,
followed by the sucrose gradient, to remove cellular components aggregated with the BTV
particles. Kowalik and Li (85) simplified the purification method for BTV. BHK-21 cells
infected with BTV were resuspended in a buffer containing 1% Triton X-100 and 0.5%
deoxycholate to lyse the cells and the cellular extracts were subjected to discontinuous
sucrose gradient separation. To obtain the purified BTV, the partially purified viruses were
treated with N-laurylsarcosinate and dithiothreitol followed by a discontinuous sucrose
gradient separation.
BTV virion particles have a sedimentation constant of 550S, and a buoyant density
in CsCl of 1.36 g/cm 2 (107, 149), or 1.38 g/cm 2 (151, 152). The core particles have a
density of 1.40 g/cm2 (110, 149).
The purified virion is composed of about 80% protein and 20% ds-RNA (151).
The BTV genome (18 x 106 daltons) consists of 10 ds-RNA segments (large segments,
L1-3; medium segments, M1-3; and small segments, S 1-4) that range in size from 0.5 to
2.7 x 106 daltons (23, 31, 153, 154).
A loss of infectivity is observed after the removal of one or more of the outer capsid
proteins (63, 153). Both monovalent and divalent cations can destabilize the outer capsid at
high ionic concentrations that are pH-dependent (65). Inactivation of BTV occurs below
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pH 6.5 (116) and the virus is most stable at pH 9 (151). This property distinguishes BTV
from reoviruses, which are stable at low pH (3, 50). BTV virions are stable in lipid
solvents (3, 141, 153) and nonionic detergents such as Triton X-100 (64, 110).

Virion proteins and RNA.

The BTV genome is surrounded by an inner core

capsid composed of two major (VP3 and VP7) and three minor (VP1, VP4 and VP6)
proteins. The outer capsid has two polypeptides, VP2 and VP5. In addition to these seven
structural proteins, four nonstructural proteins, NS1, NS2, NS3 and NS3A were found in
the infected cells (65).
The genomic ds-RNAs and viral structural proteins of BTV can be selectively
separated with a simple SDS-KCl precipitation method (98). The 10 segments of the dsRNA genome can be resolved by polyacrylamide gel electrophoresis (PAGE) into
distinctive patterns for each serotype (84, 119, 129).

From RNNRNA hybridization

analyses of ds-RNA genomes for five U.S. BTV (84) and analyses of South Mrican
serotypes (62) it can be concluded that the two outer capsid protein-coding segments, L2
and M3, showed divergence. Similar results were obtained by northern blot analyses of 21
different BTV serotypes using eDNA probes of the genome segments (59).

The

reassortment of segmented ds-RNA genome of BTV has been reported in vivo (15, 124,
142) and in vitro (82).
The molecular cloning of the genome of BTV was performed and a number of the
eDNA clones of the genes were sequenced. The sequences of the 10 segments of BTV 10
have been published (31, 35, 93, 121, 128, 168). The entire genome of five U.S. BTV
serotypes have been sequenced and analyzed phylogenetically (56, 69, 71, 72, 73, 85, 86,
87, 88, 164, 165). Analyses of the sequence data indicated that BTV-2, introduced in
Florida in 1982 (9, 36), is more distantly related than BTV-10, -11, -13, and -17, which
were isolated and found mainly in the western U.S. (71).
The immunological, molecular biological, crystallographical, and pathological
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studies about the 10 BTV ds-RNA segments and their encoded proteins are discussed
below:

Ll segment (VPl).

The size of the L1 segment is 3954 bp (128), and it

encodes the VP1 protein (46, 109, 135, 150). The predicted molecular mass of VP1 is
149.6 kDa, and it is the largest protein of BTV (128). VP1 is located at the inner core of
viral particles and is present at approximately six molecules per virion (65, 152). It is
suspected to be the viral RNA polymerase because VP1 has some amino acid sequence
homology to a vaccinia virus DNA-dependent RNA polymerase subunit, as well as to
several other known prokaryotic and eukaryotic RNA polymerases (128).

VP1 protein

expressed by a recombinant baculovirus exhibits an elongation activity by the incorporation
of ATP into the poly(U)-oligo(A) template, suggesting that VP1 is a potential viral RNA
polymerase (146).

L2 segment (VP2). The size of the L2 segment is 2926 bp in BTV-10 and -11
(34, 121), 2923 bp in BTV-17 and the six field isolates (14, 34), 2935 bp in BTV-13 and
BTV3SA-VACC (30, 42), 2943 bp in BTV-2 (162), and 2940 bp in BTV-1 (163).
Segment L2 encodes VP2, one of the outer core proteins (46, 82, 109, 135).

The

predicted molecular mass of VP2 is approximately 110 kDa and there are approximately
180 molecules per virion, as calculated by electron microscopy and image processing
techniques (52, 53, 120). Among the structural proteins of the different BTV serotypes,
the size variety was the largest for VP2 (16, 108); the predicted numbers of amino acids of
VP2 proteins varied between serotypes, such as 955 amino acids in BTV-17 (34 ), 956
amino acids in BTV-10 and 11 (34, 121), 959 amino acids in BTV-13 and 3SA-VACC
(30, 43), and 962 amino acids in BTV-1 and 2 (162, 163). Additional studies have shown
that homologies of VP2 nucleotide or deduced amino acid sequences among different
serotypes are - 55% among different serotypes (43). Peptide mapping studies of VP2 in
the different serotype of BTV also show that VP2 is unique for each BTV serotype (108).
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The outer capsid layer of BTV consists of two major proteins, VP2 and VP5. The
total molecular mass of these proteins is equivalent to about 40% of the total virion proteins
(65).

VP2 can be dissociated from the virion without removal of VP5 (64, 152),

suggesting that VP2 is more weakly associated with the core particle than is VP5.
Because VP2 is serotype-specific and a major outer core protein, it becomes a
primary serotype-specific immunogen (61,

82,

129) and also acts as a viral

haemaggulutinin (10, 28, 102). Native VP2 and a mixture of VP2 and VP5 can elicit
neutralizing antibodies in rabbit and sheep (64). The conformational determinants of both
outer coat proteins (VP2 and VP5) form the neutralizing epitopes, which interact with
neutralizing antibody (11, 112). Recombinant VP2 protein obtained from a baculovirus
expression system were also found to produce neutralizing antibodies (79). Gould and
Eaton (41) reported that the major neutralization site of the virus was located at residues
#317-335 of the VP2 protein and might be conformationally dependent, as determined by
the sequencing study of monoclonal neutralizing antibody-escape variants. Using a similar
approach, Heidner et al. (51) reported four distinct neutralizing epitopes, which likely are
included in a single antigenic domain on the VP2 of U.S. BTV-10. DeMaula et al. (17)
further described amino acid residues #208, 211, 327, and 402 of the VP2 protein as being
critical for the binding with neutralizing monoclonal antibodies, with at least two epitopes
being conformationally dependent. Rossitto and MacLachlan (125), in analyses of panels
of neutralizing antibodies, reported that multiple neutralizing epitopes exist on each
serotype of BTV.

Some of these epitopes are conserved while others vary in their

significance to the neutralization of individual BTV.

A serotype-specific neutralizing

monoclonal antibody was raised against BTV -13, and the major determinant was mapped at
residues #642-651 of the VP2 protein and was localized on the surlace of the virion as a
conformational epitope (70).

VP2 purified from an SDS-PAGE gel failed to induce

neutralizing antibodies (64).

These authors suggested that the neutralizing antibodies
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against VP2 could be conformationally dependent.

However, an oligoclonal antibody

produced against a multiple antigen peptide (MAP) consisting of 10 amino acids (residues
#646-655) caused a complete reduction in plaque formation by BTV-13, but did not with
the other four U.S.A. BTV serotypes (97). The presence of a linear, immunodominant
determinant on VP2 of BTV-13 seems likely, as does the possibility of a subunit peptide
vaccine for animals (97).
Two dual recombinant baculoviruses expressing the two outer capsid proteins VP2
and VP5 and the two core proteins VP3 and VP7 were constructed.

Then these dual

recombinant baculoviruses were used to coinfect SF-9 insect cells. When the VP2 and
VP5 genes were coexpressed in the absence of the VP3 and VP7 genes, the proteins failed
to assemble into any structure (28).

However, with coexpression of all four genes

encoding VP2, VP3, VP5, and VP7, a structure resembling whole double-shelled virus
particles was formed. Also, VP2 and VP5, each expressed alone, could interact with the
VP3NP7 core particles (28, 103). In the assembly of the virus-like particles (VLPs), the
viral nonstructural proteins (NS 1, NS2, and NS3) and the genomic ds-RNA were
apparently not required for particle formatio~ (103). In vitro cotranslation of BTV core and
capsid proteins confnmed the formation of the core-like particles (CLPs) and independent
binding of VP2 or VP5 to CLPs (101). The assembly of VLPs containing VP2 and VP5
from different serotypes was reported, which indicated that the interactive sites involved in
assembly are well conserved between the serotypes (102). Hyatt et al. (77) reported the
association of VLPs to the cell cytoskeleton as well as the release of the particles from the
infected cells in the presence of NS3/NS3A. However, CLPs (VP3 and VP7) were present
within the soluble fraction of the cells, but not associated with the cytoskeleton, evidence
that both outer proteins (VP2 and VP5) are required for a stable virus-cytoskeleton
interaction (77).

L3 segment (VP3).

The L3 segment is 2772 bp in length and encodes one of
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the major core proteins, VP3 (35, 39, 46, 71, 109, 122, 135). The predicted molecular
mass of VP3 (901 amino acids) (122) is about 103 kDa (35, 71). The estimated number of
VP3 proteins in a virion is - 60 (52, 53, 120). VP3 is a hydrophobic protein, highly
conserved among BTV serotypes (71, 108), and contains group-specific antigenic
determinants shared by the five U.S. serotypes (108).

VP3 forms the subcore, which

becomes a scaffold for another major inner core protein, VP7 (75). The three-dimensional
structure of the core particle of BTV has been analyzed using electron cryo-microscopy and
image-processing techniques ( 120). The results showed that the core has a diameter of 69
nm, icosahedral symmetry with a triangular number of 13 in a left-handed configuration,
260 knobby capsomers (composed of trimers of VP7 at the outer layer), and aqueous
channels that may provide pathways for transporting metabolites and mRNA during the
transcriptase activity of the core particles (120).
VP3 expressed in the baculovirus expression system shows that it is one of the
group-specific antigenic determinants (78, 109).

Coexpression of the inner core capsid

proteins VP3 and VP7 in insect cells led to the formation of CLPs, which were shown to
consist of a subcore of VP3 surrounded by capsomers of VP7 (29, 103). Cryo-electron
microscopic study of the synthesized CLP showed an icosahedral structure with a diameter
of 72.5 nm and with 200 VP7 triangular spikes arranged on a T
is similar to native core particles of BTV (120).

= 13,1

lattice (52), which

Subcores composed of VP3 do not

assemble in vivo in the absence of VP7, nor do VP7 trimers form any morphological
entities without VP3 (102). The three minor core proteins (VPl, VP4, and VP6) were also
incorporated into the CLP by coexpression with VP3 and VP7 (90, 102, 103). In a study
using chimeric particles expressed in insect cells after coinfection with recombinant
baculoviruses, expressing epizootic hemorrhagic disease (EHD) virus VP3 + BTV-VP7 or,
EHD-VP3 + BTV-VP7 + VP2 + VP5, the EHD-VP3 replaced the VP3 protein of BTV in
the formation of the single-shelled CLPs and double-shelled VLPs (91). The VP3 of both
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EHD virus and BTV is functionally competent and shares a high degree of homology (89,
90). Analysis of deletion mutants for VP3 showed that methionine at residue #500 and
arginine at residue #502 are both required for CLP formation (143).

Ml segment (VP4). The M1 segment gene for BTV-2, -10, -11, -13, and -17
is 1981 nucleotides (56), 30 nucleotides shorter than that of BTV-10 reported by Yu et al.
(168). VP4 is a product of the long, single open reading frame of the M1 gene (46, 56,
109, 135, 168). VP4 has 644 amino acid residues with a predicted molecular mass of
-75 kDa (56). VP4 is one of the minor inner core proteins, and the estimated numbers of
the protein per virus is 5 (65). The 5' ends of the BTV mRNAs are believed to be capped
and methylated during transcription, as in reovirus (26, 32, 137).

These enzymatic

activities are presumed to be a function of viral core proteins. VP4 is assumed to be a viral
guanylyltransferase, since it has GTP binding activity (91, 111). However, VP4 makes a
complex with GTP, not with GMP (111), which is the intermediate for the equivalent
guanylyltransferase of reovirus.

The reovirus enzyme makes covalent enzyme-GMP

complexes and transfers the GMP to the appropriate receptor molecules, with the
consequent formation of a cap structure (8, 105). A potential leucine zipper motif has also
been found in VP4 (56). However, the biological function(s) of VP4 is still not clear.

M2 segment (NSl).

The size of the M2 segment is 1769 bp in BTV-2, -10,

-11, -13, and -17, (47, 69, 94, 159) and 1770 bp in BTV-1 (44) and encodes the NS1
tubular protein (46, 69, 109, 135, 147). NS1, a 64 kDa protein, is rich in cysteine
residues, and the residues are well conserved among the different BTV serotypes (69,
129). The NS 1 protein is hydrophobic, with all of the major hydrophobic domains highly
conserved among BTV, African horse sickness virus, and Epizootic hemorrhagic disease
virus (114). NS1 exists abundantly in the BTV-infected cells (57), and the viral tubules
composed of the NS 1 proteins (60) are present predominantly in a peri- or juxtanuclear
location. The viral tubules have a diameter of 68 nm with a fine surface structure of a
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striking 9 nm linear periodicity, and are first observed in the period 2-4 h postinfection
(60). The viral tubular is believed to be attached to the intermediate filaments of the host
cell cytoskeleton (22) and are presumed to be involved in the viral replication or
transportation process. The presence of the NS 1 protein in virus and core particles, and in
fibrillar material associated with virus, which appeared to be leaving the viral inclusion
body (VIB), suggested that NS 1 may play a role in virus morphogenesis (22).
Recombinant baculovirus was used to express NS 1 protein in SF-9 insect cells, and
confirmed the formation of the tubular structure similar to those reported in BTV-infected
cells (147). Mutagenesis has shown that both the amino and carboxy termini of the NS 1
protein molecule and the cysteines at residues 337 and 340 are essential for formation of the
viral tubular structure in insect cells (113).

M3 segment (VPS).

The M3 segment is 1638 bp in length (19, 42, 54, 115,

123, 157, 165) and encodes the outer structural protein, VP5 (46, 82, 109, 135). The
complete nucleotide sequences ofM3 for BTV-2, -10,-11,-13, -17, -1AU, and -SA were
determined, and the single open reading frame of the M3 segment encodes the VP5 protein
with a calculated size of 59 kDa (526 amino acids) (13, 19, 42, 54, 115, 123, 157, 165).
The estimated number of molecules of the VP5 proteins is approximately 120 in a virion
(52, 53, 120). VP5 is enriched with nonpolar amino acids such as isoleucine and alanine
(165), and is a glycosylated protein which has been renamed GP5 ( 100, 166).

The

putative carbohydrate structures of the protein are short and unbranched (165, 166). VP5
is structurally less variable than VP2, the other structural protein located on the surface of
the virus (1 08). The combined VP2 and VP5 induced a higher neutralizing antibody titer
than VP2 alone (63, 130).

Also, analyses of reassortant and parental strains of BTV

serotype 3 and 10 in serum neutralization tests showed a major role for VP2, but also some
partial role for VP5, in the serum-neutralization (112). This indicates that VP5 enhances
immunological reaction. BTV causes severe brain malformations in fetal ruminants (104)
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and experimentally infected newborn mice (158). In a study using reassortants of two
BTV-11 that cause encephalophathy with difference of cell tropism and the ability of the
virus to invade the brain from the subcutaneous site, segment 5 correlated with the
neuroinvasiveness of reassortants when inoculated subcutaneously into newborn mice (7).
However, the function of VP5 is still unclear.

Sl segment (VP7).

The S1 segment is 1156 bp in length (85, 88, 160, 167)

and encodes one of the core proteins, VP7 (46, 109, 135), which has a predicted molecular
mass of approximately 38.5 kDa from its 349 amino acids (85, 88, 160, 167).
Approximately 780 molecules of VP7 protein exist in a virus particle (52, 53, 120). VP7 is
a prominent structural proteins of BTV (65) and extremely hydrophobic (31, 138). VP7
possesses strong group-specific determinants as determined by immunoprecipitation using
polyclonal antibodies (61). Two linear epitopes of VP7 were identified and conserved
among five U.S. BTV serotypes (99). Although VP7 is a major inner core protein (106),
its surface exposure was determined using surface labeling by iodination, and by reactivity
of intact virions with monoclonal antibodies (75, 95). Eaton et al. (20) suggested that an
amino-terminal region of VP7, near the cysteines at positions 15 and 65, is accessible at the
surface of the BTV particles in a study using immunoelectron microscopy.
VP7 has only one lysine residue (86, 167) and the lysine residue (K-255) is
conserved among five U.S. serotypes of BTV (88).

A study using expression of site-

specific and deletion mutants in insect cells demonstrated that both the lysine (K-255) and
carboxyl terminus of VP7 have important roles in the formation of core particles, composed
of the viral VP7 and VP3 (92). In the absence of the VP7 protein, VP3 did not assemble
into core-like particles in the insect cells (102). However, VP7 and VP3 can form a CLP.
The two outer core proteins, VP2 and VP5, could attach to the CLP, most likely involving
VP7 in the formation of VLP (52, 101). VP7 apparently has an important role in the viral
morphogenesis.
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The expressed VP7 protein in insect cells has been crystallized and shows that VP7
forms trimers (2) with each subunit consisting of two domains, a

~-sandwich

and a bundle

of a-helices along with a short carboxyl terminal arm, which might tie trimers together
during capsid formation (45).

The crystallographic study also suggested that the

methionine residues at the core of VP7 might provide plasticity for assembly of the virion,
and the RGD motif (167, 169, 170) might be involved in host cell attachment by BTV
during infection (45).
S2 segment (NS2 ). The length of the S2 genes of BTV-2, -11, -13, -17L, and
-170 is 1125 nucleotides (47, 164). BTV-10 and -10SA S2 genes are 1124 bp in length
(31, 48, 49). The S2 gene encodes one of the major nonstructural proteins, NS2 (46, 58,
109, 135) of 354 amino acids (164). NS2 protein has a high concentration of lysine and a
relatively low number of tryptophan and histidine residues (164).

A highly conserved

hydrophilic region is located at the carboxyl terminus of the predicted NS2 peptide
sequence for all five U.S. BTV serotypes (164), and African horse sickness and EHD
viruses (68). The cognate S2 genes are highly conserved among the five U.S. BTV
serotypes (84, 164). NS2 is phosphorylated in vivo (58, 66) and is the only virus-specific
phosphorylated protein in the infected cells (18, 57, 58, 66). The purified NS2 protein
from infected cells could be also phosphorylated in vitro and it binds to single-stranded (ss)
RNA (58, 66). Phosphoamino acid analysis showed phosphorylation of NS2 occurs only
on serine residues (18). Theron et al. (144) suggested that NS2 may be phosphorylated by
a kinase present in the cytoplasm of the virus-infected cells, not by an autophosphorylation
activity. However, the identity of the kinase remains unknown. NS2 locates primarily in
virus inclusion bodies (VIBs) and is not associated with virions (75, 145). However,
Mertens et al. (110) reported BTV 1 and 4, when purified using N-laurylsarcosine and
dithiothreitol, contain small amounts of the NS2 protein.

Baculovirus-expressed N S2

protein was reported to phosphorylate within the insect cells, and its ss-RNA binding
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ability to be independent of the protein's phosphorylation status (5, 145). However, the
functional significance of the phosphorylation of NS2 protein is not known.

Mutational

analysis of the NS2 protein expressed in insect cells showed that the frrst 40 amino acids of
the amino terminal (5), and more specifically the arginines and lysines at the amino
tenninus of the protein, are involved in the ss-RNA-NS2 interaction (169).

S3 segment (VP6). The size of S3 gene is 1046 bp in BTV-10 (31), and 1049
bp in BTV -2, -10, -11, -13, and -17 (72). The segment S3 encodes VP6 (35 kDa), one of
theminorinnercore proteins (47, 65, 109, 135). The S3 segment of BTV-10, -11, -13,
and -17 contains an open reading frame (ORF) capable of encoding a 325 amino acid
protein. However, the S3 segment of BTV-2, which also contains 1049 nucleotides, has a
longer 5' -noncoding region of 99-nucleotides and contains an ORF capable only of
encoding a 301 amino acid protein (72). VP6 is the richest of all the BTV gene products in
charged amino acids, and it is highly conserved among five U.S. BTV serotypes (31, 72).
It has a low content of asparagine, glutamine, and aromatic amino acids, as compared to
other BTV proteins, but is very rich in glycine residues (31, 72). The VP6 protein of
BTV-10, -11, -13, and -17 has no cysteine but only one cysteine is found in VP6 of BTV2 (72). Approximately 32 (152) and 37 (65) molecules of VP6 exist per virion. VP6 can

be translated by two different in-frame start codons, resulting in two VP6 peptides (VP6
and VP6a), which can be resolved on a SDS-PAGE (156).

VP6 protein expressed in

insect cells raised high titer sera, indicating that it is very immunogenic, and can be used as
a group-specific antigen (127). VP6 is present within the Vffi matrix, not with the tubular
structure (127). VP6 has been reported to contain ss- and ds-RNA and ds-DNA binding
capability (127).

However, the site(s) of the nucleic acid binding domain and the

specificity of the binding activity (such as randomness or sequence specificity) are still
unknown and remain to be determined. This nucleic acid binding activity suggests that
VP6 is involved in the encapsidation of the viral ds-RNA genome. The potential presence
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of a capping enzyme activity has been reported for inner core proteins (91, 111). VP6
might be the methyltransferase of the capping enzyme complex, and it might also have a
helicase activity, indicated by our sequence analysis of functional domains. If VP6 has a
methyltransferase and/or a helicase activity, the catalytic activities of the enzymes as well as
locations of these functional domains are still unknown.

S4 segment (NS3/3A). The S4 segment is 822 bp in length (12, 40, 73, 93,
155) and is highly conserved among BTV-2, -10, -11, -13, -17, and -1AU (73). The S4
gene encodes the two smallest nonstructural proteins, NS3 (229 amino acids, 25.5 kDa)
and NS3A (216 amino acids, 24 kDa) using in-phase and overlapping open reading frames
of the gene, which was confmned by in vitro transcription and translation of the S4 gene
(40, 109, 135, 150). NS3/3A proteins expressed in insect cells reacted strongly with sera
from sheep infected with homologous and heterologous BTV serotypes, suggesting that
these proteins are group-specific antigens (27).

Deletion of the first AUG abolishes

synthesis of NS3 but not that of NS3A (161). NS3 and NS3A are synthesized in small
amounts in the BTV-infected cell and are associated with intracellular, smooth-surfaced
vesicles, and the plasma membrane (76). Transiently expressed NS3 and NS3A proteins
in mammalian cells exist as N-linked glycoproteins containing high-mannose sugars, and
these lactosaminoglycan proteins are almost all membrane-bound (161).

Intracellular

immunofluorescence studies show that NS3 and NS3A may be transported onto the cell
plasma membrane in the presence or absence of carbohydrate chains (161). Coinfection of
SF insect cells by a recombinant baculovirus expressing the S4 gene product along with
recombinant viruses that can form VLPs, results in VLPs which bud through the cellular
membrane (77). These results suggest that NS3 proteins may play a role in the release of
BTVs from the infected cells.

Virus replication.

The replication process during BTV infection has not been

explained. However, the current knowledge and information suggest that the following
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replication process might proceed as follows: After adsorption, the viruses enter cells by
endocytosis, and the clathrin-coated vesicles are then drawn to the vicinity of the nucleus,
where the structures of outer-coat proteins VP2 and VP5 are changed and subsequently the
proteins are removed from virus particle because of the acidic condition (approximately pH
5.0) in the vesicle. The subsequent core-like particles are released into the surrounding
cytoplasm where transcription of viral RNA occurs (21, 74). The BTV mRNA species are
translated with much the same frequency as that with which they are synthesized except for
the mRNA of L1 (57). This differs markedly from reovirus, which has more than a 30fold difference between the translation and the transcription ratios of some mRNA species
(170). Translation of the RNA generates proteins that, in tum, condense with the RNA
around the parental cores to form Vffis (74). The nonstructural protein, NS2, is a major
component of Vffis and has the ability to bind ss-RNA.
condenses with ss-RNA to form VIBs.

This protein presumably

Core structural proteins are generated by the

translation of ss-RNA on neighboring ribosomes.

Condensation of proteins to form

subcores and cores probably occurs predominantly at the VIB periphery (74).

These

subcore particles are unstable and are composed of the viral genome encapsidated in a
hexagonal protein shell, with the majority of the protein mass consisting of VP3, along
with small quantities of the three minor proteins (VP1, VP4, and VP6). The innermost part
of the core consists only of the minor proteins and the 10 viral RNA species. These minor
proteins are candidates for the virus RNA-directed RNA polymerase and associated
enzymes (67), or for inhibitors of host cell metabolism. Proteins not incorporated within
these particles may remain associated with the VIBs or free in the cytoplasm. Once the
structures have been formed, the ss-RNA is copied to the ds-RNA genome. Addition of
NS 1 to the core-like particles might prevent the transcription of virion RNA or facilitate
efficient addition of VP2 and/or VP5 to the core-like particles. Outer coat proteins VP2 and
VP5 are added at the periphery of the VIBs, and this event might lead to the association of
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virus-like particles with the intermediate ftlaments of the cytoskeleton, leading to viral
transport to regions in the plasma or intracellular membranes containing NS3.

Potential

polarized presence of NS3 in host cell plasma membranes would ensure a viral release.
The release of virions from the infected cells is accompanied by either the removal of, or
conformational change in, VP2. The modification of virion-associated VP2 results in the
increased accessibility of VP7 and decreased accessibility of NS 1 (74).
JUSTIFICATION
BTV is the causal agent of bluetongue disease in domestic livestock and wild
ruminants.

The outbreaks of bluetongue disease have caused serious economic loss,

especially in the sheep industry. The study of viral proteins using current techniques in
molecular biology will provide possibilities to develop variety of strategies to diagnose the
viral infection and to prevent bluetongue disease. For instance, recombinant viral proteins
can be used as antigens to test sera from the animals suspected with BTV infection.
Purified recombinant viral outer core protein such as VP2 and VP5 can be administrated to
sheep as a subunit vaccine to protect the sheep from the viral infection. The structurefunction relationship of expressed recombinant viral enzyme can be analyzed to determine
the important sites, providing information about target sites to inhibit the viral enzyme
activity, and subsequently to suppress viral replication. Construction of the viral particles
using recombinant proteins and purified dsRNAs in vitro will elucidate the viral
encapsidation and assembly in the viral replication cycle. This information will provide
approaches to prevent formation of the virus particles in the infected cells.
Because it has ss- and ds-RNA and ds-DNA binding activity, VP6 has been
suspected to be a viral transcriptional enzyme such as methyltransferase (111) and helicase
(91). My analysis of the BTV-11 VP6 amino acid sequence using the GCG Molecular
Biology computer software program supports these hypotheses.

VP6 has two potential
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ATP/GTP binding sites, with one amino acid mismatch, and 47% sequence similarity to the
ATP-dependent RNA helicase of Saccharomyces cerevisiae.

VP6 may have ATP-

dependent helicase activity.
In the maturation process of BTV within the infected cell, one copy of each of the

10 ds-RNA segments is assembled into each progeny particle. The RNA binding activity
of VP6 suggests that it may be involved in the encapsidation activity for the 10 ds-RNAs of
the genome. Nonspecific binding of ds-DNA by VP6 suggests possible binding to host
DNA in order to interfere with the cellular macromolecular synthesis of the host.
The studies of the ds- and ss-RNA binding potential and enzyme activity for
transcriptional initiation of the ds-RNA genome are essential to understand the roles of VP6
in viral gene transcription and translation. In the previous report about the nucleic acid
binding activity of VP6 (127), purified VP6 was not used and the binding activity was
shown only on a western blot after SDS-PAGE. There are no data for the RNA and DNA
binding activity using purified VP6 under nondenaturing conditions. If the VP6 protein
has nucleic acid binding activity, the binding domains and the specificity of the binding
activity, such as random or sequence-specific binding, are still unknown.
Because VP6 is present in a very small quantity (37 molecules/virion) in BTV (65),
purification of this protein without use of detergent is difficult because of the existence of
the viral capsids, and recombinant VP6 expressed in the baculovirus expression system is
unstable ( 111 ), the potential functions of VP6 have not yet been studied except a report of
nucleic acid binding activities towards dsRNA, dsDNA and ssRNA using recombinant
VP6 in cellular lysate with membrane overlay assay (127).

There is no report about

production or usage of recombinant purified VP6 protein under nondenaturing conditions.
To initiate functional analyses of VP6 protein, the availability of large amounts of
purified VP6 is essential. Establishment of the methods to produce recombinant VP6
protein under nondenaturing conditions (133, 139) will facilitate the study of this protein.
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Injection of sufficient amounts of the purified recombinant VP6 can produce high titer
antisera in animals. The purified VP6 protein also becomes a good immunogen to produce
monoclonal antibodies (83), which can be used to defme the numbers and specific locations
of the immunodominant antigenic epitopes of VP6.

Because VP6 is a potential group-

specific antigen of BTV ( 127), immunological characterization of the protein may
contribute to the development of diagnostic reagents for bluetongue disease. Recombinant
VP6 may be used directly as antigen to test sera from infected animals. The suspected viral
enzyme activities such as helicase and methylase will be examined with the purified
recombinant VP6 in nondenaturing conditions.
The expected nucleic acid binding activity of VP6 should be confnmed using the
expressed purified protein under nondenaturing conditions. The sites responsible for each
nucleic acid binding activity are also determined to characterize domains of VP6.

The

elucidated amino acid sequences of the binding sites will provide information of nucleic
acid-protein interaction in molecular level and also provide target sites on VP6 to inhibit the
nucleic acid binding activity of the protein, leading to an inhibition of the viral replication.
Antigenic determinants of the VP6 protein should be mapped and characterized to use as a
group-specific antigen of BTV.

Determination of nucleic acid binding domains and

antigenic determinants of VP6 will provide preliminary information about structure of this
protein. Characterization of nucleic acid binding activity of VP6 will contribute to create a
more accurate model of encapsidation of viral proteins and nucleic acids in the morphogenic
events of the virus. These characterizations of VP6 will also expand the knowledge on the
study of protein-nucleic acid interactions in biochemistry as well as antigen-antibody
interaction within basic immunology.
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OBJECTIVES
The primary objective of this project is to confirm the nucleic acid binding activity
of VP6 using recombinant protein under nondenaturing conditions and to determine the
potential nucleic acid binding domains of VP6, which will initiate the investigation of
structure-function relationship of this protein. Antigenic determinants of VP6 will be also
mapped and characterized using monoclonal and oligoclonal antibodies that will be raised
with purified VP6 protein and sequence-specific oligopeptides. Using molecular cloning
techniques and protein expression systems, I will clone S3 gene into expression vectors,
and then express and purify enough VP6 protein to carry out my proposed research. To
study structure-function relationships, the deletion mutant proteins (134) of VP6 will also
be expressed and purified. I will confrrm the nucleic acid binding activity using purified
recombinant VP6 protein and map the sites responsible for the nucleic acid binding activity
using mutant proteins. The epitopes of the VP6 protein will be mapped and characterized
using VP6 specific antibodies and the purified intact and truncated VP6 proteins.

The

specific aims of this research are:
( 1) to clone the BTV -11 S3 gene into protein expression systems, and purify VP6 and
truncated mutant proteins;
(2) to confrrm the nucleic acid binding activity of native VP6 and determine the sites
responsible for this binding activity using recombinant VP6; and
(3) to map and characterize the epitopes of the VP6 protein.
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CHAPTER II
MAPPING AND CHARACTERIZATION OF ANTIGENIC EPITOPES AND
THE DOUBLE-STRANDED NUCLEIC ACID BINDING DOMAINS OF
THE VP6 PROTEIN OF BLUETONGUE VIRUSES 1
ABSTRACT
Heterologously expressed VP6 and truncated VP6 proteins of bluetongue virus
(BTV) serotype 11, purified to near homogeneity, were used for structure and function
analyses. The yield of the expressed VP6 was host cell dependent.

Six antigenic

epitopes of VP6 of BTV were identified and mapped by immunoblot analyses and
enzyme-linked immunosorbent assay with oligoclonal antibodies. These determinants
were surface accessible and conserved among the cognate VP6 proteins of five U.S. BTV
serotypes. The amino acid sequences and sizes of these six antigenic epitopes were
determined, and their precise locations were also mapped and confirmed by deletion
analyses. The nucleic acid binding activities of VP6, confitmed by electrophoretic
mobility shift assay, were concentration dependent. The binding activities and affinities
of the purified expressed VP6 protein towards double-stranded RNA and double-stranded
DNA were similar. Two domains of VP6, corresponding to three of the six antigenic
epitopes, were responsible for the nucleic acid binding activities and have been mapped
within 28 amino acids near the middle and 11 residues near the carboxyl terminus of VP6
by electrophoretic mobility shift assay and deletion mutant analyses.

Synthetic

oligopeptides corresponding to these three regions also exhibited similar concentrationdependent nucleic acid binding activities.
1

Coauthored by E. Hayama and J. K.-K. Li.
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INTRODUCTION
Bluetongue virus (BTV) is a member of the Orbivirus genus in the family

Reoviridae and is the causal agent of bluetongue disease in domestic livestock and wild
ruminants, including sheep, cattle, antelope, and deer (1, 3, 9, 19). The diffuse outer
capsid of the icosahedral BTV virion has two major polypeptides, VP2 and VP5. The
genome of BTV consists of 10 discrete double-stranded RNA (ds-RNA) segments and is
encapsidated by an inner core capsid composed of two major (VP3 and VP7) and three
minor (VP1, VP4, and VP6) proteins (17, 18, 19, 20, 24). These minor proteins are
potential and prime candidates of viral enzymes for replication and transcription.
Recently, VP1 and VP4 obtained from cell lysates have been implicated as the viral
RNA-directed RNA polymerase and guanylyltransferase, respectively (13, 22, 23).
VP6 is encoded by segment S3 (6, 18) and can be synthesized by in vitro
translation using the plus strand of segment S3 (21). This protein is the richest of all the
BTV gene products in charged amino acids, and it is highly conserved among different
BTV serotypes (8). Expressed VP6 present in insect cell lysates has been reported to
contain nucleic acid binding activity and has been found to be associated with the matrix
of virus inclusion bodies in the infected cells (20). However, these authors also reported
multiple protein contaminants were present in the cell lysates used to determine the
proposed nucleic acid binding activities of VP6 (20) and the enzymatic activities of VP1
(22) and VP4 (13). Furthermore, VP6 expressed heterologously can often be separated
into VP6 and VP6a by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) (25). The two forms of VP6 appear to represent gene products synthesized from
two different in-frame initiation codons and not by translational modification within the
eukaryotic host cells.
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The study of BTV proteins will contribute to develop strategies to diagnose the
viral infection and to prevent bluetongue disease. VP6 is one of potential candidates of
the viral enzymes for transcription and replication. Analysis of the structure-function
relationship of the VP6 protein will provide important information about target sites to
inhibit the activity. Identification and characterization of antigenic detetminants will also
indicate possible domains for protein-protein interaction. The availability of large
amount of VP6 protein in nondenaturation condition will facilitate these studies.
In order to initiate the study of the structure-function relationship of VP6 protein,
identify the antigenic determinants, and map the nucleic acid binding sites of the protein,
we cloned the full-length eDNA of the segment S3 gene of BTV serotype 11 (BTV-11)
into a prokaryotic expression vector, pGEX-2T. Large amounts of expressed VP6 and
truncated VP6 proteins were purified to near homogeneity and used for these studies.
The yield of VP6 was host cell dependent. We also identified and mapped six antigenic
epitopes with oligoclonal antibodies (OABs) as well as the nucleic acid binding
domain(s) by electrophoretic mobility shift assay (EMSA), radioimmunoprecipitation,
and deletion analysis.
MATERIALS AND METHODS

Cells and virus. The BHK monolayers were maintained in Eagle's minimum
essential medium containing 5% calf serum (Hyclone Laboratories) at 37°C in a
humidified 5% C02 atmosphere. BTV -11 virions were purified from infected BHK-21
cell mono layers grown in roller bottles infected at a multiplicity of infection of 1, for
48 h, using the method described by Kowalik and Li (10). Infected cells were scraped
from roller bottles and the suspension of the cells were centrifuged to collect cells for
2,000 rpm for 10 min. The cells were resuspended and incubated in NTE (200 mM
Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM EDTA) containing 1% (w/v) Ttiton X-100 and
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0.5% (w/v) deoxycholate at room temperature for 10 min and centrifuged to remove
cellular debris for 5 min at 1,000 rpm. The supernatant was subjected to centrifuge with
a 40% (w/v)/66% (w/w) sucrose step gradient containing 200 mM Tris-HCl, pH 8.0, in a
Beckman SW 41 Ti rotor at 39,000 rpm for 1.5 h at 4°C. Viruses were collected in the
interface between the two sucrose solutions. The partially purified virus was resuspended
and incubated in 200 mM Tris-HCl, pH 8.0, containing 1% (w/v) N-laurylsarcosine and
10 mM dithiothreitol (DTT) at 37°C for 30 min. The virus was purified by pelleting
through 40% (w/v) sucrose in 200 mM Tris-HCl, pH 8.0, by centrifugation in a Beckman
SW41 Ti rotor using the same condition described above. The purified virus was
resuspended in 200 mM Tris-HCl, pH 8.0, and stored at -20°C.

Construction of recombinant plasmids and deletion mutants. BTV genomic
ds-RNA segments were selectively isolated by SDS-KCl precipitation (14) as follows:
400 f..ll of purified virus suspension in 0.2 M Tris-HCl buffer, pH 8.0, was mixed with 44
Jll of 10% SDS, boiled for 1 min, and cooled on ice for 5 min. Then an equal volume
(444 Jll) of 0.5 M KCl was mixed with the chilled sample and continued to cool on ice for
5 to 10 min. The viral ds-RNA and proteins were separated by centrifugation at 10,000
rpm for 10 min at 4°C. The proteins were separated in the pellet. The ds-RNA in the
supernatant was further purified by phenol-chloroform (1: 1) extraction and ethanol
precipitation.
The full-length cD NA copy of the BTV-11 S3 ds-RNA segment, which codes for
VP6, was synthesized with reverse transcriptase at 420C for 1 h by using a pair of
primers containing the sequences 5'-GGATCCGAATTCGTTAAAAAATCGCATAT-3',
and 5'-GGATCCGAATTCGTAAGTGTGAAATCGCC-3'.

The eDNA was further

amplified by Taq polymerase using a modified PCR (11). In the mixture for the PCR,
approximately 0.3 Jlg of total genomic ds-RNA was mixed with these primers (0.5 Jlg
each) in 30 J.!l, boiled for 4 min to denature the ds-RNA and cooled on ice. The mixture
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was then combined with a 20 Jll of reaction mixture containing 5 Jll of lOX buffer (100

mM Tris-HCl, pH 8.3, 0.5 M KCl, 15 mM MgC1 2 , and 0.1% (w/v) gelatin, 1 JJ.l of dNTP
stock solution (10 mM each of dATP, dCTP, dGTP, and diTP), 0.5 Jll (15U) of avian
myeloblastosis virus-reverse transcriptase (AMV -RT) (Promega), and 0.5 Jll (2.5U) of

Taq polymerase (Perkin Elmer), and 13 Jll of distilled deionized water (dd-water). The
resulting solution was overlaid with a few drops of mineral oil (Sigma), and the
polymerase chain reaction was carried out in a Programmable Cycle Reactor (Ericomp
Corp.). After the synthesis of BTV cDNAs by AMV -RT as described above, the full
lengths of BTV-11 S3 cDNAs were amplified with 35 cycles of amplification step which
consisted of denaturing double-stranded nucleic acid complexes at 95°C for 2 min,
annealing at 37°C, and extension at 72°C for 3 min. Final extension was performed at
72°C for 20 min.
The PCR products were separated by agarose gel electrophoresis containing 0.5X
TBE (90 mM Tris-borate, 2 mM EDTA), and the size of the full-length eDNA of the S3
gene was confirmed by comparison with BstE 11-digested 'A DNA molecular weight
markers. The bands containing the full-length copy of the S3 gene were excised from the
gel and purified by freeze and thaw method. Briefly, the gel pieces were frozen at -20°C,
thawed at room temperature, and centrifuged at 10,000 rpm for 5 min. The S3 gene copy
in the supernatant was ethanol precipitated and dried. The eDNA copy of the S3 gene
was digested by BamH I, separated on 1% low melting agarose gel. The gel pieces
containing BamH I digested BTV-11 S3 eDNA were excised and melted at 65°C; 15 JJ.l of
gel solution containing approximately 0.1 Jlg of S3 eDNA was ligated into approximately
0.1 Jlg of BamH !-digested pGEX-2T plasmid (Pharmacia) in the 50 JJ.l reaction mixture
containing 0.5 Jll (200U) of T4 DNA ligase and ligation buffer (Tris-HCl) at 4°C
overnight.
The ligation mixture was used for transformation. The XL-1 Blue competent
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cells were prepared as follows: After the cells were grown in 20 ml of Luria-Bertaini
(LB) medium (1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 1% (w/v) NaCl)
at 37°C overnight, the bacterial culture was diluted with LB medium to 100 ml, and
grown at 37°C for additional2 h. The culture was cooled on ice for 15 min, and the cells
were collected by centrifugation at 4,000 rpm for 5 min, and the resultant pellet was
resuspended in 50 ml of ice-cold 50 mM CaC12 and kept on ice for 1 h. The cell
suspension was centrifuged at 4,000 rpm for 5 min, and the pellet was resuspended in
8 ml of 50 mM CaC12 containing 20% glycerol. The competent cell suspension was
aliquated (0.2 ml each), frozen, and stored at -80°C until use. The transformation was
carried out using a CaC12 method with the competent cells described above. Ten vl of the
ligation mixture was added to 100 J.Ll of 50 mM CaC12 and 30 mM MgC12 • Mter the
competent cells were thawed on ice, 100 J.Ll of the cell suspension was combined with the
DNA-CaC1 2 mixture, and incubated on ice for 40 min. After 2 min of heat shock at 42°C,
the cell suspension was mixed with 1 ml of LB and incubated at 37°C for 1 h.
Transformed cells were selected by ampicillin. The culture was plated on LB
plates containing 1% agar and 50 J,Lg/ml ampicillin and incubated at 37°C for overnight.
Positive colonies on the plates were picked, and grown in 2 ml of LB containing
50 J,Lg/ml ampicillin at 37°C overnight. To screen the desired colonies containing pGEX2T-B11S3 insert, the plasmid-mini prep was carried out by the following procedure:
About 1.5 ml of the overnight culture was pelleted by centrifugation at 10,000 rpm for
1 min in a microcentrifuge tube, and resuspended in 100 J.Ll of ice-cold lysis buffer (25
mM Tris-HCl, pH 8.0, 10 mM EDTA, 50 mM glucose). After incubation for 5 min at
room temperature, the cell suspension was mixed by inversion with 200 J.Ll of a freshly
prepared solution containing 0.2 N NaOH and 1% SDS and incubated on ice for 5 min.
Approximately 150 J.Ll of ice-cold potassium acetate solution, pH 4.8, was added to this
mixture and incubated on ice for 5 min with gentle mixing. The mixture was centrifuged
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at 10,000 rpm for 5 min, and the supernatant was transferred to a fresh tube. RNaseA
was added to a final concentration of 20 Jlg/ml, and the mixture was incubated at 37°C
for 30 min. Four hundred fll of Tris-HCl-saturated phenol:chloroform (1: 1) was added to
the supernatant, vortexed, and centrifuged at 10,000 rpm for 3 min. The upper aqueous
phase was transferred to a fresh tube, and 2.5 volume (1 ml) of 100% ethanol was added
to precipitate the plasmid DNA at -20°C or -80°C for 30 min to overnight. The pellet
obtained by centrifugation at 10,000 rpm for 5 min was washed with 1 ml of ice-cold
70% ethanol, and dried. The dried pellet was dissolved in 10 JJ.l of dd-water, and
subjected to restriction enzyme digestion and analysis by 1% agarose gel electrophoresis
to determine the presence of the insert.
The sequence and orientation of the insert were confirmed by dideoxy nucleotide
sequencing with the Sequenase Version 2.0 kit (U.S. Biochemical Corp.) as described
below. The sample plasmid DNA for sequencing was further purified with polyethylene
glycol (PEG) precipitation after mini-prep steps as described above except the starting
volume of the bacterial culture was 3.0 mi. To further purified plasmid, the DNA pellet
was dissolved in 16.8 fll of dd-water, mixed well with 3.2 JJ.l of 5 M NaCl, and then 20 fll
of 13% PEG 8000. The mixture was further incubated on ice for 30 min. The sample
was centrifuged at 10,000 rpm for 10 min at 4°C. The pellet was rinsed with 1 ml of icecold 70% ethanol, centrifuged for 1 min, and dried under vacuum. The dried pellet was
dissolved in 20 fll of dd-water, and the DNA solution was mixed and incubated with 15.2
JJ.l of a freshly prepared solution containing 2N NaOH and 2 mM EDTA for 5 min at
room temperature to denature the DNA. The denatured DNA was mixed with 8 fll of
1 M Tris-HCl, pH 4.5, and 3 fll of 3 M sodium acetate on ice. After mixing with 75 Jll of
ice-cold 100% ethanol, the DNA sample was incubated -80°C for 30 min. The tube was
centrifuged at 4°C for 5 min to pellet the denatured DNA, which was then washed with
200 JJ.l of ice-cold 70% ethanol and dried under vacuum.
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The dried DNA (approximately 3 to 5 Jlg) was mixed with 1 fll of appropriate
primer (0.5 to 1.0 pmol), 2 Jll of 5X sequenase sequencing buffer (200 mM Tris-HCl, pH
7.5, 100 mM MgC1 2 , 250 mM NaCl), and 7 fll of dd-water. The sample (annealing mix)
was mixed well and incubated at 37°C for 30 min. During this incubation, the following
reagents were prepared: Four tubes per DNA sample, each containing 2.5 Jll of one of the
four termination mixes (ddGTP, ddATP, ddTIP, and ddCTP), were prepared and prewarmed at 37°C. The stock sequenase was diluted 1:8 with ice-cold TE (10 mM TrisHCl, 1 mM EDTA, pH 7.5). The labeling mix (7.5 J.!M dGTP, 7.5 J.!M dCTP, 7.5 J.!M
dATP, and 7.5 J.!M dTIP) was also diluted 1:5 with dd-water. Each labeling reaction mix
contained 1 fll of 0.1 M DTT, 2 fll of each of the four labeling mix dilution, 0.5 fll (4 fJ.Ci)
of [ 35 S]dATP, 2 f.!]. of sequenase, dilution and 10 fll of the DNA template/primer mix, and
incubated at room temperature for 5 min for the labeling reaction to proceed. About 3.5
fll of each of four termination mixes was added to the labeling reaction and incubated at
37°C for 5 min.

The reaction was terminated using 4 fll of stop solution (95%

formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) and the
sample was stored at -20°C until use. To denature the DNA, the reaction products were
heated at 70°C for 10 min and chilled on ice before loading onto a sequencing gel
containing IX TBE, 7 M urea, and 5% acrylamide (acrylamide:bicacrylamide, 60: 1).
Then 2.5 fll of sample was loaded per lane onto the sequencing gel, and run at 2,000 V
with lX TBE at about 60°C until appropriate separation was obtained.

After

electrophoresis, the sequencing gel was transferred to a piece of Whatman
Chromatography 3MM Chr paper, and soaked for 15 min in 5% acetic acid and 15%
methanol to remove the urea. Then, the gel was dried at 80°C using slab gel dryer (BioRad, Model 483) for approximately 2 h. The dried gel was exposed with Kodak XAR-5
film overnight to obtain autoradiography.
C-terminal deletion mutants were constructed with the Erase-A-Base system
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(Promega) as follows: Using the information from the physical map of the cognate S3
genes of five U.S. BTVs (8), the BTV-11 S3 insert within pGEX-2T-B11S3 plasmid was
digested with Kpn I and Hind III to produce an exonuclease III (Exo III) (Promega)
resistant 3' overhang end and unprotected 5' overhang end in the linearized plasmid.
These two restriction enzymes do not digest the vector pGEX-2T. The Kpn I site is
located within 3' noncoding region and Hind III is located at close to the termination
codon of the S3 gene. After each restriction enzyme digestion, the plasmid was purified
by phenoVchloroform extraction and ethanol precipitation. An aliquot of the digested
plasmid DNA was analyzed electrophoretically to confirm the complete digestion of the
plasmid. Five JJ.g of the linearized pGEX-2T-BllS3 plasmid was dissolved in 60 J.!l of
Exo III IX buffer (66 mM Tris-HCl, pH 8.0, 0.66 mM MgC1 2), and then 1 JJ.l (300U) of
Exo III was mixed with the plasmid solution to digest the 5' protruding end of the DNA
at 15°C as suggested by the manufacture's protocol (p. 95 in Protocols and Application
Guide, Second Edition, Promega). At 30-second intervals, each 7.5 JJ.l of the Exo III

reaction mixture was transferred to the tube containing 22.5 J.!l of S 1 nuclease mix (-7 U
of Sl nuclease, 40 mM potassium acetate, pH 4.6, 333 mM NaCl, 1.35 mM ZnS04 ,
6.75% glycerol) and put on ice to stop the Exo lli digestion. After eight Exo lli digests
were collected, the DNA samples were incubated at room temperature for 30 min to
remove the single-stranded tails remaining after the Exo lli digestion. The digestion was
terminated by the addition of 3 JJ.l of S 1 stop buffer (0.3 M Tris base, 0.05 M EDTA). To
generate blunt end in the DNA, 3 JJ.l of Klenow mix (0.3 U of Klenow DNA polymerase,
20 mM Tris-HCl, pH 8.0, 100 mM MgC1 2) was added to the DNA sample and the tube
was incubated for 3 min at 37°C, followed by the addition of 3 JJ.l of dNTP mix (0.125
mM each of dATP, dCTP, dGTP, and dTTP). After incubation at 37°C for 5 min, each
DNA sample was purified with phenol:chloroform (1: 1) extraction and ethanol
precipitation. The dried DNAs were digested by Sma I to remove the nucleotide
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sequence between the Kpn I and Sma I site that is adjoined to the BamH I insertion site
within the multiple cloning sites in the pGEX-2T vector. The digested DNAs were again
purified with phenol:chloroform (1: 1) extraction and ethanol precipitation.

The

precipitated DNA was subjected to ligation, transformation to XL-1 Blue cells, and
selection by the LB agar plate containing ampicillin as described above. Expressions of
the truncated proteins by the positive colonies after induction with 0.1 mM IPTG were
screened by SDS-PAGE as described below. Plasmid mini-prep and EcoR I digestion,
followed by gel electrophoresis was used to confirm the successful insertion of the
truncated DNA in the colonies.
To produce site-specific C-terminal deletion mutants of BTV -11 S3 gene in the
pGEX-2T vector, the pGEX-2T-B11S3 plasmid was digested with Sph I and Nco I,
respectively, and purified with phenol:chloroform (1: 1) extraction and ethanol
precipitation. The linearized plasmids were further digested with Sma I to remove
approximately half of S3 gene located close to the 3' end, and then purified with
phenol:chloroform (1:1) extraction and ethanol precipitation. Blunt ends of the purified
DNAs were produced using Klenow DNA polymerase and dNTP as described before.
DNAs were purified followed by ligation, transformation, selection, and screening steps
as described above.
According to the information from the physical map of the cognate S3 genes of
five U.S. BTVs (8), the BTV-11 S3 insert was digested with Sph I and Nco I to produce
internal deletion mutant of S3. The Sph I and Nco I sites are located at immediate
upstream and downstream of #71 region of the BTV -11 S3 insert. These two restriction
enzymes do not digest the vector pGEX-2T.

After the double restriction enzyme

digestion, the linearized DNA was treated with Klenow DNA polymerase and dNTP to
generate blunt ends as described above. The DNA was purified with phenol:chloroform
(1: 1) extraction and ethanol precipitation, and subjected to ligation, followed by
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transformation to XL-I blue as described above. All deletion mutants were sequenced
across the deletion junctions to locate and confrrm the sites of deletion.
Expression and purification of VP6 and truncated VP6 proteins. Glutathione

S-transferase (GST) Gene Fusion System (Pharmacia) was used to express and purify the
VP6 protein of BTV -11. The following are optimized conditions for 1 L of culture:
E. coli harboring the pGEX-2T-B 11S3 plasmid with confirmed orientation of the S3

insert was cultured initially in 200 ml of LB medium containing 50 J.tg/ml of ampicillin at
270C overnight and 800 ml of LB medium containing 50 J,tg/ml of ampicillin was added
the next morning. After incubation for an additional 1 h, 0.1 mmol of isopropyl-~-D
thiogalactopyranoside (IPTG) was added to the bacterial culture to induce expression of
BTV-11 VP6 protein in the cells, which were incubated for additional 3 h. The cells
were harvested by centrifugation at 4,000 rpm for 10 min at 4°C. The pellet was
resuspended in 50 ml of ice-cold #1 buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl,
and 150 mM EDTA), and centrifuged again at 4,000 rpm for 10 min at 4°C. The cell
pellet was resuspended in 15 ml of the #1 buffer, and then sonicated five times (30 sec
each) in ice bath with 1-min incubation intervals on ice between each sonication. The
sample was centrifuged at 4,000 rpm for 15 min and the supernatant was mixed with
about 10 ml of ice-cold glutathione-agarose beads (G-beads) (Sigma) containing #1
buffer. The cell pellet was again resuspended in 15 ml of #1 buffer, sonicated, and
centrifuged as described above. The second supernatant was also mixed with the G-bead
suspension in a 50-ml tube and the expressed glutathione-S-transferase-VP6 (GST-VP6)
fusion proteins in the bacterial lysate were extracted using the G-beads at 4°C overnight
with gentle rocking. The G-beads was washed extensively three times with (a) 40 ml of
ice-cold #1 buffer, (b) 40 ml of 100 mM Tris-HCl, pH 7.5, 150 mM NaCl buffer (#2
buffer), and (c) 40 ml of 100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaC1 2 buffer
(#3 buffer). The intact VP6 protein was released from the G-bead-bound fusion protein
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by digestion with bovine thrombin (Sigma). Briefly, 10 ml of G-bead-fusion protein
suspension (-50% )-in #3 buffer was incubated with 10 ~g of bovine thrombin at 25°C for
4 h. After incubation the suspension was centrifuged at 4,000 rpm for 5 min at 4 °C. The
supernatant was removed and then filtered through a 0.45

~m

syringe filter to remove any

residual G-beads in the supernatant. The purified VP6 was concentrated by Aquacide
(Sigma) at 4°C and stored in #3 buffer at -80°C until use. The truncated VP6 proteins
from segment S3 deletion mutants were also expressed and purified as the intact VP6
protein.

Polyclonal (PAB), and oligoclonal antibody (OAB) production. PAB and
OABs against VP6 were produced as previously described (7, 16, 26). Heterologously
expressed and purified VP6 protein and synthetic peptides were used as immunogens to
produce polyclonal and oligoclonal antibodies in rabbits. To produce OABs, six different
synthetic peptides were synthesized in the multiple antigen peptide format (7, 16, 26).
The amino acid sequences of these six immunogens are ERLRDLRRKEKSE,
ERGGRKQRKE,KENKTEPKEESK,REGVEEEKTSEE,KEEGGKETKDADVDRR,
and KEY AREASKKK (see Fig. 5), and their corresponding OABs are designated as
OAB #70, 71, 72, 73, 74, and 75, respectively. The purified VP6 protein (0.5 mg) or
each of six synthetic peptides (0.5 mg) in 0.5 ml of 1X phosphate-buffered saline (PBS)
was mixed with 0.5 ml of complete Freund's adjuvant, and injected into a rabbit
subcutaneously, respectively. Booster injection with incomplete adjuvant containing 0.5
ug of purified VP6 protein, or each of six synthetic peptides, was performed 2 to 3 weeks
after the first injection. High titer OAB sera were obtained after the frrst booster and
rabbits were bled out after the third booster. For PAB production against purified intact
VP6, two additional booster injections were performed and the rabbit was then sacrificed.
These antisera were used for immunoblot detection and ELISA without further
purification. However, antisera OAB #7 5 was further purified to prepare antibody
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coupled protein A-beads. The protocol to purify antibody with ammonium sulfate
precipitation was described in chapter 8 of Antibodies by Harlow and Lane (4).
Approximately 0.5 ml of saturated ammonium sulfate was slowly added to one ml of
antiserum. After incubation overnight at 4°C, the mixture was centrifuged at IO,OOO rpm
for I 0 min. The pellet was discarded. The supernatant was transferred to two tubes and
0.25 ml of saturated ammonium sulfate was added to each tube. After incubation
overnight at 4 °C, the tubes were again centrifuged. The supernatant was removed and
discarded. The two IgG pellets were dissolved in a total of 0.5 ml of IX PBS . The
antibody solution was transferred to a dialysis tubing and dialyzed against three changes
of 500 ml of IX PBS at 4°C. After dialysis, the antibody solution was centrifuged at
IO,OOO rpm for 5 min to remove any remaining debris. The purified antibody solution
was adjusted to I ml with IX PBS.

Analysis of VP6 by SDS-PAGE, immunoblots, ELISA, and immunoprecipitation. The protocols used to analyze the intact and the truncated VP6 proteins
by SDS-PAGE, immunoblots, and enzyme-linked immunosorbent assay (ELISA) were
similar to those employed in our laboratory (7, I6, 26). The Laemmli (I2) discontinuous
SDS-PAGE was used to separate proteins. Double immunoblots were generated using
diffusional sandwich technique overnight at room temperature using blotting buffer
containing 25 mM Tris, 192 mM glycine, and 20% methanol. For ELISA, 50 Jll of
purified VP6 protein (100 J.@'ml) in 10 mM sodium carbonate buffer, pH 9.6, was used to
"coat" polyvinyl plates (96 wells), and incubated overnight at 4°C. The plate was
washed six times with IX PBS containing 0.05% Tween-20 (PBS-T). The plate was
"blocked" with 200 Jll of 3% bovine serum albumin (BSA) in PBS-T for 1 h at 37°C.
The plate was washed twice with 200 Jll of PBS-T. One hundred Jll of I0" 1, I0- 2 , I0- 3 ,
IO

4

,

I0- 5 , and I0-6 diluted OABs were added to duplicate wells, and incubated for 90 min

at room temperature. The plate was washed four times with 200 Jll of PBS-T. Horse
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radish peroxidase (HRP)-conjugated second antibody against rabbit IgG was added and
incubated at 37°C for 1 h. The plate was washed four times with 200 J..Ll of PBS-T. Two
tablets of OPD Chromaphore (Hyclone Laboratories) and 0.1 ml of 3% hydrogen
peroxide solution were dissolved in 10 ml of deionized water, and 100 J..Ll of this substrate
solution was added to each well.

The plate was incubated for 20 min at room

temperature, and detected at 490 nm using an ELISA reader (Dynatech).
Mter isotopically labeled nucleic acids were incubated with purified VP6 for

30

min at 30°C, the reaction complex was immunoprecipitated for 1 hat room temperature
with monospecific OAB (#75) which was covalently coupled with protein A-conjugated
Sepharose beads, and washed with 200 J..Ll of #3 buffer. The protocol described in chapter
13 in Antibodies (5) was used to prepare protein A bead-antibody coupling. Briefly, 0.5
ml of purified OAB #75 solution was mixed with 0.5 ml of protein A-beads in 1X PBS
and incubated at room temperature for 1 h with gentle mixing. The beads were washed
with 5 ml of 0.2 M sodium borate, pH 9.0, twice and pelleted by centrifugation at 4,000
rpm for 5 min. The beads was resuspended in 5 ml of 0.2 M sodium borate, pH 9.0.
Dimethylpimelimidate was added to a final concentration of 20 mM and the mixture was
incubated at room temperature for 30 min with gentle rocking. After the incubation, the
beads were collected by centrifugation at 4,000 rpm for 5 min and the reaction was
stopped by washing the beads in 5 ml of 0.2 M ethanolamine, pH 8.0. The beads were
again resuspended in 5 ml of 0.2 M ethanolamine, pH 8.0, and incubated for 2 h at room
temperature with gentle mixing. The beads were collected by centrifugation as above,
resuspended in lX PBS to make 50% slurry, and stored at 4°C until use.

The

radioactivity of the VP6-nucleic acid complexes was determined by scintillation
counting, and the components of these complexes were identified by 10% SDS-PAGE
followed by either autoradiography or silver staining.

Electrophoretic mobility shift assay (EMSA). BTV ds-RNA for the binding
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studies were terminally labeled as described by Li et al. (15). Phenol-chloroform
purified ds-RNA (10 J.tg) was used for labeling with 50 J.lCi of cytidine 3' ,5'[32P]bisphosphate (5'-e2P]pCp) in 50 mM Tris-HCl, pH 7.8, 10 mM MgC1 2, 10 mM 2mercaptoethanol, 1 mM ATP, and 10% dimethyl sulfoxide (DMSO) at 37°C for 1 h.
After the reaction, 3' end

32

P-labeled ds-RNA was treated with phenol-chloroform

purification and ethanol precipitation.
Various amounts of purified intact and truncated VP6 proteins and sequencespecific synthetic peptides in 100mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaC12
buffer were used for reactions with different double-stranded nucleic acids, including
BTV ds-RNA and nonviral ds-DNA, at 30°C for 30 min.

The changes in the

electrophoretic mobilities of the 32 P-labeled BTV ds-RNA were analyzed by 4%
nondenaturing (polyacrylamide:bisacrylamide, 60: 1) gel electrophoresis containing 0.5X
TBE (45 mM Tris-borate, 1 mM EDTA) buffer with initial running for 30 min at 50 V
followed by 100 V for 45 min using a mini gel system. The gel was transferred to a piece
of 3MM paper and dried for about 2 h at 80°C, followed by autoradiography. The
mobility shift of nonviral ds-DNA fragments after binding VP6 proteins was analyzed
with 0.8% agarose gel containing 0.5X TBE, and visualized by ethidium bromide
staining after the electrophoresis.
RESULTS

Production and purification of the expressed BTV VP6 and truncated VP6
proteins. Full-length eDNA of segment S3 of BTV-11 was inserted into the BamH I site
of pGEX-2T under the control of the tac promoter. The induced intracellular glutathione
S-transferase-VP6 fusion protein was recovered from bacterial lysates by affinity
chromatography with glutathione-agarose beads. The VP6 moiety of the bound fusion
protein was cleaved by thrombin. Since the released VP6 in the supernatant contained an
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additional 13 amino acids (GSEFVKKSHRSAA) at its amino terminus, the expressed
VP6 was slightly larger than the virion VP6. Analyses of the amino acid composition
indicated that the estimated molecular masses of the cognate VP6 and VP7 protein were
approximately 36 kDa (8) and 39 kDa (11), respectively. However, the smaller VP6
migrated distinctly more slowly than the larger VP7 protein in SDS-PAGE, a mobility
that was inconsistent with standard gel electrophoresis.

We attribute the slower

electrophoretic mobility to the unique amino acid composition of VP6: it contains few
aromatic amino acids but many glycines (40 of 325 amino acids) and abundant charged
residues (e.g., arginine, lysine, and histidine), which slowed down its migration and gave
an apparent molecular mass of 44.5 kDa. With the additional 13 amino acids from the
anchor PCR primer sequence present in the plus noncoding region of S3 gene, the
expressed VP6 appeared to be 46 kDa in SDS-PAGE.
The level of expression of VP6 differed among the bacterial host strains. From
multiple independent transformants, more VP6 was produced using the TOPP-2 strain
(Stratagene) (Fig. 1, lanes 3, 6, 9, and 12) than the SURE strain (Novagen) (lanes 2, 5, 8,
and 11), which in tum was better than the XL-1 blue (Invitrogen) (lanes 1, 4, 7, and 10).
Approximately 3 to 4 mg of soluble and purified VP6 could be obtained per liter of
TOPP-2 bacterial culture. The expressed VP6 from cells grown at between 32 and 37°C
(Fig. 2, lanes 3, 4, 6, 7, 8, and 9) or without 100 mM EDTA in the lysis step (Fig. 3, lanes
2, 3, and 4) was unstable and easily degraded. When the bacterial culture was grown at
25 to 27°C, the purified VP6 isolated after a 4 h incubation with thrombin at room
temperature was stable for at least 6 to 8 h at room temperature. However, a degraded
fragment of VP6 appeared frequently in different preparations. Thus the expression and
production of truncated VP6 proteins were conducted at 250C with the TOPP-2 E. coli
host.
To confirm that the expressed protein was VP6 of BTV, we performed gel
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1 2 3 4 5 6 7 8 9 10 1112
kDa

Ex.VP6

Fig. 1. Differential expression of VP6 in three different E. coli host cells. Three
different E. coli hosts (XL-1 Blue, SURE, and TOPP-2) were transformed with pGEX-2T
plasmid containing the BTV-11 S3 gene insert. GST-VP6 fusion proteins present in the
celllysates of XL-1 Blue, SURE, and TOPP-2 host cells (lanes 1, 2, and 3) were affinity
purified by GST-agarose beads (lanes 4 to 6). Lanes 7 to 9 are VP6 proteins released
from the GST-VP6 fusion proteins obtained from XL-1 Blue, SURE, and TOPP-2 cells
after thrombin digestion. Note the different amounts of VP6 expressed in these three host
cells. The identity of the VP6 protein is confirmed by Western blot analysis using
monospecific anti-VP6 serum (lanes 10 to 12).
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Fig. 2. SDS-PAGE analysis of expressed VP6 fusion proteins grown at different
growing temperatures. Expressed VP6-GST fusion proteins grown at different growing
temperatures (25°C, 33°C and 3'f>C) were analyzed by SDS-PAGE (10%
polyacrylamide). Molecular weight markers are in lane 1. The E. coli lysates containing
GST-VP6 fusion protein expressed at 25°C, 33°C and 37°C, respectively, were prepared
in standard SDS-PAGE sample buffer without sonication (lanes 2, 3, and 4). GST
proteins in the bacterial lysates after sonication (lanes 5, 6, and 7) and extracted with
glutathione conjugated beads (G-beads) (lane 8, 9, and 10) are shown in the order of the
bacterial growing temperature, 25°C, 33°C and 37°C.
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1 2 3 4 5 6 7
Expressed
GST-VP6

Fig. 3. Effect of additional EDTA in the lysis buffer to cellular lysate containing
expressed VP6 fusion proteins. VP6-GST fusion proteins expressed in XL-1 blue were
analyzed by SDS-PAGE (10% polyacrylamide). E. coli cells containing expressed VP6GST fusion protein were pelleted, resuspended, sonicated in 100 mM Tris-HCl-150 mM
NaCl buffer with different concentration of EDT A (0, 25, 50, 100, and 200 mM), and the
fusion proteins were extracted with glutathione conjugated beads in lanes 2 to 6,
respectively. The E. coli lysate sample was prepared in standard SDS-PAGE sample
buffer without sonication (lane 1). Molecular mass markers (lane 7).
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electrophoresis, followed by immunodetection. The molecular weight of the protein was
similar to that of the virion VP6 in SDS-PAGE (Fig. 4), and reacted with oligoclonal
anti-VP6 (see Fig. 1, lanes 10 to 12, and Fig. 8, lane 1) and polyclonal anti-BTV sera(Fig.
4, lane 1). Furthermore, polyclonal antibody against purified VP6 reacted specifically
and only with the expressed VP6 and cognate VP6 proteins of five U.S. BTV serotypes
(Fig. 4, lane 2 to 6).
Soluble intact and truncated VP6 proteins were obtained, purified to near
homogeneity, and analyzed by SDS-PAGE as shown in Figs. 1 and 5. The expected
molecular mass of each truncated VP6 protein corresponded to the coding capacities of
each deletion mutant. When approximately 90 amino acids (1 0 kDa) were removed from
the carboxyl terminus of the purified expressed VP6, a cryptic protease-sensitive site was
exposed, resulting in a peptide with an estimated molecular mass of 23 kDa (Fig. 5, lanes
5 to 8). An arginine residue located at residue #151 or 163, which represents the trypsinsensitive site, might be the cryptic site.

Identification and mapping of antigenic epitopes conserved among five U.S.
BTV serotypes. Six oligopeptides, corresponding to six potential antigenic determinants
predicted by Genetics Computer Group (2) computer software analyses of deduced amino
acid sequences of cognate VP6 proteins (8), were synthesized in the multiple antigen
peptide format (16, 26) and then used to produce six OABs (OABs #70 to 75) in rabbits.
The amino acid sequences of these six synthetic peptides and their locations are shown in
Fig. 6. The sequence-specific OABs were used to analyze and map the antigenic epitopes
of VP6 and truncated VP6 proteins by Western blot (immunoblot) and ELISA. In Fig. 7
it is evident that OABs #70 and 75 (1: 1,000 dilution) reacted with VP6 proteins of five
U.S. BTV serotypes. As shown in Fig. 8, OABs #70, 71, 73, and 75 (1:1,000 dilution)
reacted well with purified intact VP6 (Fig. 8, lane 1) and truncated VP6 proteins (Fig. 8,
lanes 2 to 9). These four regions could represent linear epitopes or linear components of
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Fig. 4. Immunoblot analysis of VP6 of five U.S. BTV using polyclonal antibody
against VP6. Polyclonal antibody (1:1000 dilution), made in rabbits against purified VP6
heterologously expressed in E. col, was used to react with cognate VP6 proteins from five
purified U.S. BTV-2, 10, 11, 13, and 17 virions in Western blots (Fig. 3, lanes 2 to 6).
The lane 1 contained the expressed GST-VP6 fusion protein, thrombin digested VP6
proteins and degraded VP6 peptide fragments. Expressed VP6 contains 13 additional
amino acids from the carboxyl terminus of the GST protein in its amino acid end, and
thus migrates slower than the virion VP6. Note similar reactivity is observed among the
cognate VP6 of five U.S. BTV. Pre-immune serum from the same rabbit was used in Fig.

4-B.
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30.0
21.5

23k

14.3

14k

Fig. 5. SDS-PAGE analysis of truncated BTV VP6 proteins. Purified truncated
VP6 proteins expressed heterologously were analyzed by SDS-PAGE (20%
polyacrylamide). C-terminal deletion mutants #6, 20, 4, 34, 31, 2, and 1 are present in
lanes 3 to 9, respectively. Molecular mass markers (lane 1), intact VP6 (lane 2), and
internal deletion mutant #36 (lane 10) are also shown. A cryptic protease-sensitive site
was exposed, resulting in a 23 kDa peptide (lanes 5 to 8).
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peptide

Residue
Location

72

35-46

JtENKTEPKEESK

74

63-78

JtEEGGKETJtDADVDRR

Peptide Sequence

70

181-193

ERLRDLRRKEKSE

71

200-209

ERGGRXQRKE

73

216-227

REGVEEEJtTSEE

75

292-302

JtEVAREASKKK

Fig. 6. Location of six potential antigenic epitopes on VP6 protein of BTV. The
locations of six potential antigenic determinants are predicted by the Genetic Computer
Group computer program from the deduced amino acid sequence of VP6. Synthetic
peptides corresponding to amino acid sequences of these six epitopes were synthesized to
use as immunogens for the production of OABs and to map the nucleic acid binding
domains of VP6. The locations and sequences of amino acid residues of 6 oligopeptides
were also shown in the table.
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Fig. 7. Western blot analyses of VP6 of five U.S. BTV by oligoclonal antibodies
of VP6. OABs #70 (Fig. 6A) and #75 (Fig. 6B) (1:1,000 dilution) detected VP6s of five
U.S. BTV serotype specifically. Each BTV serotype was indicated on top of the blot.
BTV VP6 proteins in panel A were detected with OAB #70 and anti-rabbit antibody
conjugated with alkaline phosphatase as a second antibody followed by p-nitroblue
tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) color
substrates. The BTV VP6 proteins in panel B were reacted with OAB #75 and anti-rabbit
antibody conjugated with horse radish peroxidase as a second antibody followed by
luminal and hydrogen peroxide, and then the blot was exposed with X-ray film.
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Fig. 8. Western blot analyses of intact and truncated VP6 proteins. Capillary
sandwich blots made from gels shown in Fig. 3 were incubated with OABs #70, 71, 73,
and 7 5 (1: 1,000 dilution). The location of the antigenic epitopes recognized by these four
OABs are shown in Fig. 2. Intact VP6 is in lane 1. C-terminal deletion mutants #6, 20,
4, 34, 31, 2, and 1 are in lanes 2 to 8, respectively. Lane 9 contains internal deletion
mutant#36.
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conformational epitopes. However, OABs #72 and 74 did not react with the denatured
VP6 proteins immobilized on nitrocellulose membrane.
To determine whether the antigenic determinants recognized by these six OABs
are surface accessible on the native VP6, we used these six OABs in ELISA analysis
(Fig. 9). OABs #73, 74, and 75 reacted strongly. Moderate and weak reactions were
detected with OABs #70 and 72, respectively. However, OAB #71, which reacted
strongly with denatured VP6, did not bind to the native VP6 in the ELISA, an indication
that amino acid residues #200 to 209 may be a linear or internal and surface-inaccessible
determinant. The three antigenic determinants recognized by OABs #73, 74, and 75 are
potential linear epitopes on the surface. The combined results of Western immunodetection and ELISA also indicated that the determinant recognized by OAB #7 4 is a
surface-accessible and conformational epitope.

Nucleic acid binding activity of BTV VP6 protein. VP6 expressed in the
baculovirus expression system exhibits nucleic acid binding activity and is associated
with the matrix of the virus inclusion bodies (20).

However, unpurified VP6

contaminated with many cellular proteins was used in this membrane overlay assay, and
the domains responsible for the nucleic acid binding activity have not been identified or
mapped. To locate the nucleic acid binding domains of VP6, we made a series of
C-terminal and internal deletion mutants of VP6 and purified the heterologously
expressed VP6 and truncated VP6 proteins to homogeneity (Fig. 4). We then used those
purified VP6 proteins to locate and map the domains responsible for nucleic acid binding.
The nucleic acid binding activity of BTV VP6 was determined initially by
radioimmunoprecipitation; i.e., isotopically labeled BTV ds-RNA was incubated with
purified VP6. The nucleic acid-protein complex was precipitated with OAB #75,
incubated with protein-A agarose beads, and then pelleted. After extensive washing, the
mixture was boiled and analyzed by SDS-PAGE followed by autoradiography. Purified
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dilution of serum
Fig. 9. Binding of anti-VP6 OABs to purified VP6 in ELISA. Expressed purified
VP6 was immobilized to the bottom of individual wells of a 96-well plate before OABs
were added. The amount of binding of VP6 by these OABs was measured by the binding
of enzyme-conjugated goat anti-rabbit antibodies. OD490, optical density at 490 nm.
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VP6 could bind to all of the ten 3'-end-labeled BTV-11 ds-RNA segments. The amount
of BTV ds-RNA that was bound and precipitated was proportional to the amount of
purified VP6 protein. When RNase A was included in the reaction mixture, no label was
detected, which confirmed that the nucleic acid bound by VP6 protein was BTV ds-RNA
(Fig. 10).
Specific nucleic acid binding activities of purified BTV VP6 proteins were further
investigated using EMSA. As shown in Fig. 11, the binding of VP6 retarded the
migration of the labeled BTV ds-RNA proportionally to the amount of VP6 used in the
mobility shift assay. Similar results were obtained with nonviral ds-DNA (Fig. 12). The
amount of VP6 required to affect the migration of 1 ng of BTV ds-RNA and nonviral dsDNA was 10 and 30 ng, respectively. However, the ds-DNA fragments (0.1 to 8.5 kb)
were slightly larger than BTV ds-RNA (0.8 to 4.0 kb). These results suggested that VP6
is a nucleic acid binding protein. The specificity of the nucleic acid binding activity was
further demonstrated and confmned by competition with unlabeled RNA or DNA. As
shown in Figs. 13 and 14, the mobility of the labeled ds-RNA was retarded when
different amount of unlabeled ds-RNAs (Fig. 13) and ds-DNAs (Fig. 14) were used for
competition. To further characterize ds-RNA binding activity of VP6, VP6 protein was
examined for nucleic acid binding activity in the presence of high concentration of NaCl,
urea, guanidinium hydrochloride as well as anionic detergent SDS (Figs. 15 to 18). As
shown in Figs. 15 to 18, VP6 still has binding activity towards ds-RNA in the presence of
1.35 M NaCl, 8.0 M urea, or 4.8 M guanidine HCl, but not in the presence of 0.1% SDS.

Localization and mapping of nucleic acid binding domains of VP6 by
deletion analysis. To locate and map the domains on the VP6 protein that are
responsible for nucleic acid binding, we constructed a series of C-terminal and internal
deletion mutants. The expressed truncated VP6 proteins purified from the bacterial lysate
were used to determine how C-terminal and internal deletions affected nucleic acid
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Fig. 10. Immunoprecipitation of BTV ds-RNA-VP6 complexes. Isotopically
labeled BTV ds-RNA (10 ng) was incubated for 1 hat room temperature with different
amounts of purified VP6 protein followed by the addition of OAB #75. This complex
was collected by Protein-A Sepharose. The samples were analyzed by 10% SDS-PAGE
and autoradiographed. Note that the increase of ds-RNA binding was proportional to the
amount of VP6 used. No signal could be detected when RNase A (1 J..Lg) was added to the
complex for 30 min at room temperature (lane 8), confirming the presence and identity of
BTV ds-RNA in the immunocomplex. L: large segments of ds-RNA; M: medium
segments of ds-RNA; S: small segments of ds-RNA.
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Fig. 11. Nucleic acid binding activity of purified VP6 protein, as determined by
ds-RNA EMSA. Different amounts of purified VP6 proteins of BTV-11 were used for
reactions with 10 ng of 3'-end-labeled BTV-11 ds-RNA for 30 min at 300C before the
reaction mixtures were analyzed by 4% nondenaturing PAGE and autoradiography. The
retardation of the electrophoretic mobilities of ds-RNA by purified VP6 were dosage
dependent. BSA, bovine serum albumin. L: large segments of ds-RNA; M: medium
segments of ds-RNA; S: small segments of ds-RNA.

71

1 2 3 4 5 6 7 8 9 10

ds-DHA

+ + + + + + + + + +

VP6

(ug)

-

BSA

(ug)

-

o.06 o.uo.25 o.5 1.0 2.0 t.o a.o -

-

-

-

-

-

-

-

a.o

Fig. 12. Nucleic acid binding activity of purified VP6 protein, as determined by
ds-DNA EMSA.

BstE II-digested phage 'A DNA (0.3 JJ.g) incubated with different

amounts of purified VP6 was analyzed by agarose gel electrophoresis and visualized by
ethidium bromide staining. The retardation of the electrophoretic mobilities of ds-DNA
by purified VP6 were dosage dependent. BSA, bovine serum albumin.
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Fig. 13. Competition of the ds-RNA binding activity of VP6 by unlabeled dsRNA. The specificity of ds-RNA binding activity of VP6 towards labeled BTV ds-RNA
was demonstrated by the addition of various amounts of unlabeled BTV ds-RNA. Note
the absence of mobility shift for labeled ds-RNA of BTV as shown in EMSA when 1.6 J.lg
of ds-RNA was used. L: large segments of ds-RNA; M: medium segments of ds-RNA;
S: small segments of ds-RNA.
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Fig. 14. Competition of the ds-RNA binding activity of VP6 by unlabeled dsDNA. The specificity of ds-RNA binding activity of VP6 towards labeled BTV ds-RNA
was demonstrated by the addition of various amounts of unlabeled nonviral ds-DNA.
Note the absence of mobility shift for labeled ds-RNA of BTV as shown in EMSA when
1.0 to 2.0 j.lg of ds-DNA was used. L: large segments of ds-RNA; M: medium segments
of ds-RNA; S: small segments of ds-RNA.
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Fig. 15 Nucleic acid binding activity of purified VP6 protein under high NaCl
concentration. Purified VP6 proteins of BTV-11 were reacted with 20 ng of 3'-endlabeled BTV -11 ds-RNA in the presence of different concentrations of NaCl. The other
experimental conditions are similar to Fig. 11. Note VP6 still showed binding activity
toward ds-RNA in the presence of 1.35 M NaCl. L: large segments of ds-RNA; M:
medium segments of ds-RNA; S: small segments of ds-RNA.
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Fig. 16. Nucleic acid binding activity of purified VP6 protein under high urea
concentration. Purified VP6 proteins of BTV-11 were reacted with 20 ng of 3'-endlabeled BTV -11 ds-RNA in the presence of different concentrations of urea.
Experimental conditions are similar to Fig. 11. Note VP6 still showed ds-RNA binding
activity in the presence of 8.0 M urea. VP6 protein was boiled for 3 min before mixing
with ds-RNA (lane 9). The reaction mixture was boiled for 3 min before loading to gel
(lane 10). Lanes 9 and 10 showed L: large segments of ds-RNA; M: medium segments
of ds-RNA; S: small segments of ds-RNA.
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Fig. 17. Nucleic acid binding activity of purified VP6 protein under high
concentration of guanidine HCI. Purified VP6 proteins of BTV -11 were reacted with 20
ng of 3 '-end -labeled BTV -11 ds- RNA in the presence of different concentrations of
guanidine HCI. Experimental conditions are similar to that presented in Fig. 11. Note
VP6 protein still showed ds-RNA binding activity in the presence of 4.8 M guanidine
HCI.

77

1 2 3 4 5 6 7 8 9 10

L

M

s

32 P-ds-RHA(20 ng>
VP6 (1.5 ug)

SDS (%)

+ + + + + + + + + +
+ + + + + + + + +
-0.0010.0050.010.050.1 0.5 1.0 2.0

Fig. 18. Nucleic acid binding activity of purified VP6 protein in the presence of
SDS. Purified VP6 proteins of BTV-11 were reacted with 20 ng of 3'-end-labeled BTV11 ds-RNA in the presence of different concentrations of SDS. Experimental conditions
are similar to Fig. 11. Note the complete loss of nucleic acid binding activity for VP6 in
the presence of 0.1% SDS.
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binding (Fig. 19). The specific binding of these truncated VP6 proteins to ds-RNA and
ds-DNA as determined by EMSA indicated that mutant #31 lost its nucleic acid binding
activity following the deletion of amino acid residues #195 to 212 (Fig. 19, lane 7).
However, retention of the region in mutant #34 did not result in the loss of the binding
activity (Fig.19, lane 6). The amino acid sequence in this region is rich in lysine and
arginine and is highly conserved among the cognate VP6 proteins of the five U.S. BTV
serotypes. Furthermore, when residues #195 to 210 were deleted in mutant #36, there
was a considerable loss of binding activity (Fig. 19, lane 10). The binding activities for
these truncated VP6 proteins are summarized in Table 1.

ds-RNA and ds-DNA binding activities of synthetic peptides of BTV VP6.
The results cited above suggested that the nucleic acid binding domain of VP6 resides in
the carboxyl portion of the protein. To further identify the domains responsible for
binding activity, we used sequence-specific VP6 peptides, 10 to 15 residues in length, in
EMSA. As shown in Fig. 20, there was no binding with synthetic peptides #72, 73, and
74 (lanes 4 to 6). However, oligopeptide #70, 71, and 75 could bind to ds-RNA and
retarded its electrophoretic mobility (Fig. 20, lanes 2, 3, and 7). Similar results were also
obtained with ds-DNA (Fig. 21). Thus, there might be two domains within the carboxyl
portion of VP6 that are responsible for ds-RNA and ds-DNA binding activities;
oligopeptide #70 and 71 are adjacent to each other but are more than 80 amino acids
away from oligopeptide #75.
Because native VP6 exhibits concentration dependent binding towards BTV dsRNA and nonviral ds-DNA (Figs. 11 and 12), we determined whether the binding
activity of oligopeptides #70, 71, and 75, which are rich in arginine and lysine, was also
concentration dependent. Various amounts of synthetic pep tides were incubated with 10
ng of BTV ds-RNA (Fig. 22) and nonviral ds-DNA (Fig. 23) in EMSA. The nucleic acid
binding activities of all these oligopeptides were concentration dependent. Furthermore,
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16 120 14 134 131 12 11 136

Fig. 19. ds-RNA binding activities of purified truncated VP6 proteins of BTV -11.
Purified truncated BTV VP6 proteins (1.5 Jlg each) were used in EMSA under conditions
similar to those described for Fig. lOA. #6, 20, 4, 34, 31, 2 and 1 are C-terminal
truncated VP6 proteins ordered by descending of the size. #36 is a internal truncated
VP6. Intact and C-terminal truncated #6, 20, 4 and 34 VP6 proteins (lanes 2 to 6)
showed ds-RNA binding activities. C-terminal truncated #31, 2 and 1 proteins (lanes 7 to
9) did not show ds-RNA binding activity. C-terminal region of #34 truncated protein was
removed in the internal truncated protein (#36). The internal truncated VP6 protein (lane
10) also lost the ds-RNA binding activity.
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TABLE 1. Summary of ds-RNA and ds-DNA binding activity of VP6, its truncated
deletion mutants, and sequence-specific oligopeptides
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32

P-ds-RHA

(lO Dg)

oligopeptide
(2 ug)

+ + + + + + +
-

70 71 72 73 74 75

Fig. 20. ds-RNA binding activity of VP6-specific synthetic peptides. The dsRNA binding activities of six sequence-specific synthetic peptides (2 f.lg) were
determined by EMSA and autoradiography. Oligopeptides #70, 71, and 75 could bind to
ds-RNA (lanes 2, 3, and 7). The experimental conditions used were similar to those
described for Fig. 1OA.
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1 2 3 4 5 6 7

+ + + + + + +

ds-DHA
oligopeptide _ 70 71 72 73 74 75
( 5 ug )

Fig. 21. ds-DNA binding activity of VP6-specific synthetic peptides. The dsDNA binding activities of six sequence-specific synthetic peptides (2

~g)

were

determined by EMSA. Oligopeptides #70, 71, and 75 could bind to ds-DNA. The
experimental conditions used were similar to those described for Fig. lOB.
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Fig. 22. Concentration dependent ds-RNA binding activity of VP6 sequencespecific oligopeptides. Various amounts of synthetic oligopeptides #70, 71, and 75
corresponding to the domains of VP6 were tested for their binding activities to ds-RNA
(10 ng) under experimental conditions identical to those described for Fig. lOA.
Oligopeptides #70, 71, and 7 5 showed concentration dependent binding activity to dsRNA with slightly different affinity.
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Fig. 23. Concentration dependent ds-DNA binding activity of VP6 sequencespecific oligopeptides. Experimental conditions are similar to those described in Fig. 22
except ds-DNA (0.3 IJ.g) was used. Oligopeptides #70, 71, and 75 are concentration
dependent in binding activity to ds-DNA with slightly different affinities.
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concentrations of oligopeptides #71 and 7 5 (Fig. 22, B and C) that affected the mobility
of BTV ds-RNA appeared to be lower than concentrations of oligopeptide #70 (Fig. 22).
Similar results were obtained with ds-DNA (Fig. 23).

Because the domains

representedby oligopeptide #70 and 71 (residues #181 to 209) and #75 (residues #292 to
302) both exhibit binding activities, there are two unique nucleic-acid binding sites or a
single conformational site composed of both domains. A summary of the ds-RNA and
ds-DNA binding activity of VP6 sequence-specific peptides is shown in Table 1.
DISCUSSION
The inner core of the BTV virion contains only 30 to 40 molecules of VP6
proteins (6, 19, 24). The limited availability of this protein has hindered the study of
functions and structure. In this study, we heterologously expressed VP6 and several
truncated VP6 proteins of BTV -11 in E. coli. However, the yield and solubility of these
proteins depended on the E. coli host cells. TOPP-2 cells (Stratagene) consistently
yielded more VP6 proteins than did many other E. coli host cells (unpublished data). The
yield of heterologously expressed VP6 and truncated VP6 proteins was higher at 37°C.
However, these soluble proteins were highly unstable at this temperature. Lowering the
growth temperature to 25 to 270C reduced the yield but increased the stability and
homogeneity (>98%) (Fig. 5, lane 2). The average yield is about 3 to 4 mg of purified
VP6 protein per liter of bacterial culture.
The purified VP6 protein from E. coli celllysates was highly immunogenic and
elicited high-titered monospecific polyclonal antisera, which readily recognized cognate
virion VP6 proteins from five U.S. BTV serotypes in Western blot analysis (Fig. 4). The
purified VP6 truncated proteins exhibited similar antigenicities and produced excellent
antisera for mapping of the epitopes (Fig. 8).
The purified VP6 protein was relatively stable when stored at -70°C. However,
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removal of more than 90 amino acids from the carboxyl terminus (e.g., mutants #4, 34,
31, and 2) resulted in partial degradation of the truncated VP6 proteins (Fig. 5, lanes 5 to
8). There was a prominent peptide fragment with an estimated molecular mass of
23 kDa, an indication that the deletion of 90 amino acids in the carboxyl terminus
exposed an internal or cryptic protease-sensitive site, perhaps the two arginine residues
#151 and 163. However, a conformational change associated with the deletion of
residues #195 to 210 (mutant #36) resulted in the loss of nucleic acid binding activity
(Fig. 19, lane 10), but did not diminish the stability of the truncated protein (Fig. 5, lane
10). This indicates that the potential cryptic protease-sensitive site was not exposed.
We produced six OABs from multiple antigen peptide-synthesized peptides. At a
dilution of 1:1,000-1:2,000, four OABs (#70, 71, 73, and 75) reacted well with denatured
VP6 and truncated VP6 proteins in Western blots (Fig. 8), perhaps because these peptides
represent either linear epitopes or important components of conformational determinants.
The lack of reactivity against VP6 in Western blots by OABs #72 and 74 indicated that
these two epitopes could be conformational. When these six OABs interacted with native
VP6 proteins in ELISA, the reactivities associated with surface accessibility were strong
to moderate for all except OAB #71 (Fig. 9). The epitope recognized only in a Western
blot, but not in ELISA, by OAB #71 is more likely to be internally located.
The nucleic acid binding activities of highly purified VP6 proteins were
concentration dependent (Figs. 11 and 12), and the specificity of this binding was
confirmed by competition with unlabeled nucleic acids (Figs. 13 and 14). We used
purified truncated VP6 proteins and sequence-specific synthetic peptides in EMSA to
locate the one or two domains responsible for nucleic acid binding activities (Figs. 19 to
23). The first domain appeared to reside within 29 residues between the residues #181
and 209, corresponding in location to synthetic peptides #70 and 71. The second domain
was located between residues #292 and 302 (KEV AREASKKK) near the carboxyl
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terminus of the VP6 protein, corresponding to peptide #75.

Both domains are

hydrophilic and rich in arginine and lysine, a characteristic of many DNA-binding
proteins. The amino acid sequences of these two domains in the cognate VP6 proteins of
five U.S. BTV serotypes (Fig. 24) have high sequence conservation and only minor
conservative substitutions.
Several factors indicate that the nucleic acid binding domain of BTV VP6 could
be single but conformational: (i) deletion of residues #292 to 302 (mutant #6) did not
affect the binding activity (Table 1); (ii) deletion of residues #195 to 210 alone eliminated
the binding activity; (iii) each of the three synthetic peptides (residues #181 to 193, #200
to 209, and #292 to 302) bound nucleic acid; and (iv) residues #200 to 209 were not
surface accessible because they were not recognized by anti-VP6 serum in ELISA (Fig.
9), but the regions represented by residues #181 to 192 and #292 to 302 were located on
the surface of VP6 (Fig. 9). Thus, amino acid residues #292 to 302, when juxtaposed
with residues #181 to 193 and #200 to 209, may form a conformational domain that
enables nucleic acid binding. We hypothesize that the deletion of residues #292 to 302
(mutant #6) did not markedly change the conformation of residues #181 to 209.
However, deletion of residues #195 to 210 (mutant #36) markedly changed the
conformation and eliminated binding activity (Table 1). The crystallization of VP6 and
truncated VP6 proteins is now under way to examine these hypotheses.
The cloning, expression, and purification of large amounts of intact and truncated
VP6 proteins to homogeneity will help us elucidate the biological roles and structurefunction relationships of the other two minor core proteins, VP1 and VP4. The cognate
VP6 proteins of five U.S. BTV serotypes contain two unique domains separated by a
glycine-rich region. The nucleic acid binding activity in the C-terminal domain may
potentially facilitate encapsidation of the 10 ds-RNA segments. Even though VP6 binds
BTV ds-RNA, it is probably not a nucleocapsid protein because each virion apparently
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sites from five U.S. BTV serotypes.
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contains only 30 to 40 molecules (6, 19, 24). The ds-DNA binding activity of VP6 may
interfere or down regulate host cellular metabolism by suppression of the host gene
expression. The 40 to 45% residue similarity and 20 to 25% sequence identity of VP6
with several known methylases indicate that VP6 protein might be a component of the
capping enzyme complex that caps and methylates the 5' ends of the BTV mRNA species
during transcription. There is also a motif common to several helicases near the glycinerich region. Future research should investigate whether VP6 possesses ds-RNA helicase
activity, which would unwind BTV ds-RNA segments before RNA transcription and
replication.
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CHAPTER III
IDENTIFICATION OF THE CONFORMATIONAL EPITOPES AND SINGLESTRANDED NUCLEIC ACID BINDING SITES OF THE VP6 PROTEIN OF
BLUETONGUE VIRUS SEROTYPE 11

ABSTRACT
Four surface-accessible, conformational antigenic determinants of the VP6 protein
of bluetongue virus (BTV) serotype 11 were characterized and mapped with four monospecific monoclonal antibodies against VP6 using Western blots and ELISA. Intact VP6
and truncated VP6 proteins heterologously-expressed by a prokaryotic expression vector
were purified. The single-stranded nucleic acid binding sites of the VP6 protein were also
identified using these intact and truncated VP6 proteins.

There were two domains

responsible for this binding activity between residues #181 to 209 and #292 to 302 ofVP6,
which were mapped by deletion mutants, electrophoretic mobility shift assay (EMSA), and
membrane overlay assay.

Synthetic oligopeptides corresponding to these sites also

exhibited similar specific single-stranded DNA- and RNA-binding activities in a
concentration-dependent manner. A previous report (6) indicated that these two domains
were also responsible for the double-stranded nucleic acid binding activity of VP6 protein.
However, differences in the binding and affmity towards double- and single-stranded
nucleic acids may reflect different biological functions of this unique viral protein during
BTV infection cycle.
INTRODUCTION
Bluetongue virus (BTV) is a prototype virus of the Orbivirus genus in the family
Reoviridae (9) and the causal agent of bluetongue disease in domestic livestock and wild
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ruminants (1, 5, 9, 16). The BTV genome consists of 10 ds-RNA segments that range in
size from 0.5 x 106 to 2.7 x 106 daltons (2, 20, 21). The genome is surrounded by an
inner core capsid composed of two major (VP3 and VP7) and three minor (VP1, VP4, and
VP6) proteins. The outer capsid has two polypeptides (VP2 and VP5). In addition to
these seven structural proteins, there are four nonstructural proteins, (NS1, NS2, NS3,
and NS3A) in the infected cells (18). NS3 and NS3A are the products of the S4 gene of
BTV (3, 14, 23).
The viral capping enzyme activity reportedly resides in the inner core proteins (12,
15). Three minor inner core proteins are potential and prime candidates for viral enzymes
of replication and transcription. VP1 is a putative viral RNA polymerase (19).

VP4

probably is the viral guanylyltransferase, as indicated by GTP-binding activity (12, 15).
Since VP6 exhibited single-stranded (ss) and double-stranded (ds) RNA and ds-DNA
binding activity (6, 17), it may also be a viral transcriptional enzyme (6).

The deduced

amino acid sequences of the cognate VP6 proteins of the five U.S. BTV serotypes (6) have
two potential ATP/GTP binding sites (residues #100 to 107 and 114 to 121) with one
amino acid mismatch (residues #107 and 120).

Our analysis of deduced amino acid

sequence of VP6 protein also indicated VP6 has 47% residue similarity to the ATPdependent RNA helicase of Saccharomyces cerevisiae, suggesting that VP6 might have
ATP-dependent helicase activity.
VP6 is the richest of the BTV gene products in charged amino acids and its
sequence is highly conserved among the five U.S. BTV serotypes (4, 8). VP6 can be
translated from two different in-frame start codons of the viral mRNA, resulting in two
VP6 proteins (VP6 and VP6a), which can be resolved by SDS-PAGE (22). The cellular
location of VP6 is within the virus inclusion body (VIB) matrix, and not with the tubular
structure (17). VP6 protein expressed in insect cells elicits high-titer antisera, an indication
of its immunogenicity (17).

We have mapped and characterized the double-stranded

95
nucleic acid binding domains, using deletion mutants and synthetic peptides, and identified
six antigenic linear epitopes of the VP6 protein using oligoclonal antibodies (6). These six
detenninants are consetved among the cognate VP6 proteins of all five U.S. B1V
serotypes, suggesting that VP6 is a group-specific antigen. This is consistent with previous
RNNRNA hybridization results (10). In this study, we further identified and mapped the
domains of VP6 responsible for single-stranded nucleic acid binding activity, and
determined their affinities toward different forms of RNA and DNA.
MATERIALS AND ME1HODS

Cells and virus. BTV-11 virions were purified from infected BHK-21 cell
mono layers at a multiplicity of infection (m.o.i.) of 1 and grown in roller bottles for 48 h,
using methods described previously (8, 11, 13, 24) and in chapter II of this dissertation.

Construction of recombinant plasmids and deletion mutants.

The

method used to construct pGEX-2T (Pharmacia) containing BTV-11 S3 eDNA insert and
the carboxyl terminal and internal deletion mutants have been previously described by
chapter II of this dissertation. The two additional internal deletion mutants #37 and #38
were generated using the following two primers: (a) 5' -GCTGAATGCTGGAGGAGGAGGTGGA-3' and (b) 5'-GCTGAATGCTGGAACGAATGGAAGA-3' in addition to the
two primers used in our previous study (6). We used these primers and PCR to produce
two site-specific internal deletions of the BTV -11 S3 eDNA, which lacked nucleotide
sequences corresponding to the first or both of the putative ATP/GTP binding domains
(nucleotides #328 to 348 and 328 to 390, respectively). The PCR products were digested
with Hind III and Bsm I, and then ligated to Hind III+ Bsm !-linearized pGEX-2T-B11S3
DNA to generate pGEX-2T-B11S3 mutant plasmids. All deletion mutants were sequenced
across the deletion junctions to locate and confirm the sites of deletion (6). The pGEM7ZfBTV-11 S3 plasmid was generated with insertion of S3 eDNA digested with BamH I at the
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corresponding multiple cloning site of the pGEM7Zf plasmid. The constructed pGEM7ZfBTV-11 S3 plasmid was used to produce a runoff transcript of BTV-11 S3 using the
condition as described below.

Synthesis of labeled S3 ss-transcripts. For the binding studies,

32

P-labeled

S3 ss-RNA (plus and minus sense transcripts) were prepared in vitro in a reaction mixture
containing either 17 or SP6 RNA polymerase (NE-BioLabs), in the presence of 1 J,!g of
linearized pGEM7Zf-B11S3 plasmid template, 100 J.LCi of [a- 32P] GTP (NEN), 400 mM
each of the four nucleoside triphosphates, 1 mM dithiothreitol and 56 U RNase inhibitor
(USB) in 1X polymerase reaction buffer (NE-BioLabs). After incubation for 2 h at 37°C,
5 U of RNase-free DNase I was added and incubation continued for 15 min. The RNA
transcripts were recovered by phenol-chloroform extraction and isopropanol precipitation.
Smaller

32

P-ss-RNA runoff transcripts (78 bases) were also prepared using 17 RNA

polymerase and BamH I-linearized pGEM7Zf plasmid as a template and conditions similar
to those used to synthesize full-length S3 transcripts.

Expression and purification of VP6 and truncated VP6 proteins.
Heterologously expressed intact VP6 and truncated proteins were purified from cellular
lysates using the method as described in chapter II of this dissertation.

Monoclonal antibody (MAB) production.

MABs against VP6 were

produced as previously described (7, 13, 24) using expressed and purified VP6 protein (50
J,!g) in 0.5 ml of 1X PBS as an antigen. Anti-VP6 monoclonal antibody clones (C16.1.1,
D12.4.20, D34.5.7 and H13.1) in ascites fluid were determined to be IgG1, IgG2a,
IgG2a, and IgG 1 isotypes, respectively. These monoclonal antibodies in ascites fluid were
used for immunoblots and ELISA without further purification. To apply these monoclonal
antibodies for supershift in electrophoretic mobility shift assay (EMSA), purified IgGs
were obtained by 3X ammonium sulfate (40%) precipitation and extensive dialysis against
PBS at 4°C before use.
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Analysis

of

VP6

by

SDS-PAGE,

immunoblots,

ELISA,

and

membrane overlay nucleic acid binding assay. The protocols used to analyze the
intact and the truncated VP6 proteins by SDS-PAGE, and to prepare immunoblots using
nitrocellulose membrane and enzyme-linked immunosorbent assay (ELISA), were similar
to those employed in our laboratory (6, 7, 13, 24) and chapter II of this dissertation. For
the membrane overlay binding assay, the denatured VP6 proteins in the SDS-PAGE gels
were renatured by incubation twice with 25 mM Tris-HCl, 192 mM glycine, 20% methanol
at room temperature for 30 min, and the proteins were then blotted onto nitrocellulose
membranes using the same buffer. After the blots were blocked with the binding buffer
(10 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, 0.1% Triton X-100, 0.02% BSA, 0.02%
Ficoll400, 0.02% polyvinylpyrrolidone, pH 7 .5) at room temperature for 1.5 h, they were
incubated with 32 P-labeled S3 ss-transcript (plus and minus sense, respectively) at room
temperature for 1.5 h. The unbound probes were removed by washing the blots twice with
the binding buffer for 5 min at room temperature.

Autoradiograms were obtained by

exposing Kodak XAR- fJ.lm to the dried blots overnight.

Electrophoretic mobility shift assay (EMSA). The general conditions for
EMSA were similar to those in chapter II of this dissertation.

The sequence-specific

peptides #70, 71, 72, 73, 74, and 75 were synthesized in the multiple antigen peptide
(MAP) format, and peptides A, B, C, D, and E were made in linear form.

For gel

retardation analysis, various amounts of purified intact and truncated VP6 proteins or
sequence-specific synthetic peptides in 100 mM Tris-HCl, 150 mM NaCl, 2.5 mM CaC12
(pH 7 .5) buffer were used to interact with different ss-nucleic acids, including ss-RNA
extracted from yeast (Mann Res Lab, NY), 32P-labeled S3 full-length plus and minus sense
transcripts, 78 base ss-transcript and M13mp18 circular ss-DNA (NE-BioLabs) at room
temperature for 5 min. The changes in the electrophoretic mobilities of the
transcripts

(78

bases

m

length)

were

analyzed

by

4%

32

P-labeled

nondenaturing

98
(polyacrylamide:bisacrylamide = 60: 1) gel electrophoresis using 0.5X Tris-borate-EDTA
(TBE) buffer and the bands were visualized by autoradiography.
mobility shift of the

32

The electrophoretic

P-labeled S3 full-length plus and minus transcripts was analyzed

with 4% denaturing (polyacrylamide:bisacrylamide = 60: 1) gel electrophoresis containing 6
M urea. The mobility shift of ss-RNA extracted from yeast and M13 ss-DNA after binding
by VP6 proteins and peptides was visualized by ethidium bromide staining of the 0.8%
agarose gel with 0.5X TBE after electrophoresis.
RESULTS

Mapping and characterization of antigenic epitopes of VP6 by four
monoclonal antibodies (MABs).

The heterologously expressed intact and truncated

VP6 proteins were purified to near homogeneity as determined by SDS-PAGE (Fig. 25).
The 23 kDa peptide represents the exposure of a cryptic protease-sensitive site when more
than 90 amino acids are deleted from the carboxyl terminus of VP6 (6).
produced four monospecific anti-VP6 monoclonal antibodies (C16.1.1,

We recently
012.4.20,

D34.5.7 and H13.1), which were used to characterize and map the potential conformational
antigenic epitopes of VP6 by Western blot and ELISA. As shown in Fig. 26, four MABs
reacted distinctively with the expressed and purified VP6, as well as with truncated VP6
proteins on immunoblots. Two internal deletion mutant proteins #37 and 38 with amino
acid residues deleted from #101 to 107 and #101 to 121 (removal of the first, and then
both, ATP/GTP binding domains, respectively), also reacted well with these four MABs
on Western blots (data not shown). MAB C16.1.1 reacted strongly with truncated VP6
proteins from C-terminal deletion mutants #6, 20 and 36 (Fig. 26, lanes A-2, 3, and 9), as
well as with intact VP6 (lane 1).

However, this MAB reacted moderately with the

truncated proteins from the C-terminal deletion mutants #4, 34, 31 and 2 (Fig. 26, lanes A4, 5, 6, and 7), and reacted very weakly with that from #1, the smallest C-terminal
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Fig. 25. SDS-PAGE analysis of purified intact and truncated BTV VP6 proteins.
Purified truncated VP6 proteins expressed heterologously were analyzed by 18% SDSPAGE. Molecular mass markers are in lane 1, and intact VP6 in lane 2.

C-terminal

deletion mutants #6, 20, 4, 34, 31, 2 and 1 are present in lanes 3 to 9, respectively.
Internal deletion mutants #36, 37 and 38 (lanes 10 to 12), and BTV -11 viral proteins (lane
13) are also shown.
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Fig. 26. Western blot analysis of purified and truncated B1V VP6 proteins by
monoclonal antibodies.

The immunoblots were incubated with MABs C16.1.1 (A),

012.4.20 (B), 034.5.7 (C) and H13.1 (D) in ascites fluids (1:1,000 dilution) followed by
incubation with anti-mouse antibody conjugated with alkaline phosphate (1: 10,000
dilution). Lane 1 shows intact VP6 protein. C-terminal deletion mutant proteins #6, 20, 4,
34, 31, 2 and 1 are shown in lanes 2 to 8, respectively. In lane 9 is shown internal deletion
mutant#36.

truncated protein (Fig. 26, lane A-8).
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Thus MAB C16.1.1 apparently recognized a

conformational determinant that spanned the amino acid residues #77 and 325 of
VP6.MAB D 12.4 20 reacted well with all of truncated VP6 proteins as well as with intact
VP6 (Fig. 26, B). This indicated that the major antigenic determinant recognized by MAB
D12.4.20 was located at theN-terminus of VP6 (amino acid residues #1 to 77). MAB
D34.5.7 reacted only with the intact VP6 (Fig. 26, lane C-1) and the internal deletion
mutant #36 (Fig. 26, lane C-9), but not with any of the C-terminus truncated proteins (Fig.
26, lanes C-2 to 8). Thus the potential antigenic determinant recognized by this MAB was
located at the C-terminus of VP6 (amino acid residues #284 to 325). MAB H13.1 reacted
well with C-terminal deletion mutants #6 and 20 (Fig. 26, lanes D-2 and 3), as well as with
the intact VP6 and internal deletion mutant #36 (Fig. 26, lanes D-1 and 9) but not with
other truncated VP6 proteins. The major antigenic determinant recognized by MAB H13.1
appeared to be located between amino acid residues #234 and 269.
When viral proteins of purified viruses were used in immunoblots, MAB C 16.1.1
did not react with VP6 proteins of the five U.S. BTV (Fig. 27, A). However, MABs
D12.4.20, D34.5.7 and H13.1 reacted strongly with VP6 proteins of all five U.S. BTV
serotypes on Western blots (Fig. 27, B, C and D). The purified expressed VP6 proteins
have an additional13 amino acids (GSEFVKKSHRAA) at their amino termini (6). These
additional amino acid residues probably affected the conformation of the antigenic
determinant recognized by the MAB C 16.1.1. We further attempted to map the locations of
these antigenic epitopes by competitive immunodetection of VP6 on Western blot using 11
sequence-specific oligopeptides (see Table 2) as competitors according to the method
described by Yang et al. (24). However, none of these 11 oligopeptides competed with
these four MABs (data not shown). Thus these four MABs did not react with these 11
oligopeptides, which represented 40% of the 338 amino acid residues of VP6 and were
evenly distributed throughout the protein.
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Fig. 27. Western blot analysis of VP6 proteins of five U.S. BTV by monoclonal
antibodies.

Five U.S. BTV proteins were immunoblotted and incubated with MABs

C16.1.1 (A), D12.4.20 (B), D34.5.7 (C), and H13.1 (D) in ascites fluids with
experimental conditions similar to Fig. 2. VP6 ofBTV-2, 10, 11, 13, and 17 are shown in
lanes 1 to 5.
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Table 2. Summary of nucleic acid binding activity of sequence-specific oligopeptides of
BTVVP6

Peptide Location

Bindin& A~liviti

NH 2

Peptide Seguence

10-19

A KRSSEELKQR

35-46

72 KENKTEPKEESK

63-78

74 KEEGGKETKDADVDRR

101-115

B

DRGDGKVGGGGGDAD

142-153

c

KYGTKIDVYRDE

181-193
200-209
216-227

70 ERLRDLRRKEKSE
71 ERGGRKQRKE
73 REGVEEEKTSEE

252-262

D ERKNAPIGARE

292-302
313-323

75 KEVAREASKKK
E DAKTEFLRLFD

I

COOH

ssRNA ssDNA

+
+

+
+

+

+
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To determine whether the antigenic determinants recognized by these four MABs
were surface-accessible epitopes on VP6, we conducted an ELISA analysis using purified
intact VP6 protein (Fig. 28). Three of the MABs, 034.5.7, 012.4.20 and H13.1, reacted
strongly. MAB C16.1.1 reacted moderately. These results suggested that at least three of
these four antigenic determinants are surface-accessible. The results of ELISA (Fig. 28)
and Western blots (Figs. 26 and 27), indicated that these four antigenic determinants
recognized by the MABs are distinct and surface-accessible, but they are different from the
six linear epitopes previously determined and characterized by six oligoclonal antibodies
(6).

These four epitopes contained between 36 to 77 residues, and were potentially

conformational.

ss-RNA and ss-DNA binding activities of purified BTV VP6 protein.
The potential ss-RNNDNA binding activity of the purified VP6 protein was determined
using EMSA. As shown in Fig. 29 the binding of VP6 retarded the migration of the yeast
ss-RNAs directly and proportionally to the amount of VP6 used in the mobility shift assay.
Similar results were obtained with
30). Approximately 10

~g

32

P-labeled negative sense BTV-11 S3 transcripts (Fig.

of VP6 was required to completely retard 1

ss-RNA transcript (Fig. 31). The amount of VP6 (26

~g)

~g

of the 78 base

used in this experiment did not

completely retard the mobility of all of the ss-RNA extracted from yeast (Fig. 29, lane 8).
Purified VP6 protein also bound to and retarded the mobility of the M13 circular ss-ONA in
a concentration-dependent manner (Fig. 32). The mobility shift of M13 circular ss-ONA
was evident when the ratio ofVP6 and ss-DNA was 1:1 (Fig. 32, lane 3). The retardation
of the ss-ONA-VP6 complex increased when more VP6 was added (Fig. 32, lanes 3 to 9).
Our preliminary calculations indicated approximately 100 Jlg of VP6 protein is required to
totally complex 1 Jlg of the M13 circular ss-ONA. These EMSA results confmned that
VP6 binds ss- nucleic acids as well as ds- nucleic acids as reported previously (6).
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Fig. 28. Reactivity of four MABs with purified VP6 in ELISA. The purified VP6
protein was immobilized onto the bottoms of wells of a 96-well plate and different dilutions
of monoclonal antibodies in ascites fluid were added. The reactivity of these MABs against
VP6 was measured by the horse radish peroxidase-conjugated goat anti-mouse antibodies.
Optical density was measured at 490 nm.
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Fig. 29. Single-stranded nucleic acid binding activity of the purified VP6 protein as
determined by ss-RNA EMSA. Different amounts of purified VP6 proteins of BTV-11
were used for reactions with 20 JJ.g of ss-RNA extracted from yeast for 5 min at room
temperature before the reaction mixtures were analyzed by
electrophoresis and visualized by ethidium bromide staining.

0.8%

agarose gel

The retardation of the

electrophoretic mobilities of ss-RNA by purified VP6 was dosage dependent.
serum albumin (BSA) was used as a negative control.

Bovine
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Fig. 30. Single-stranded nucleic acid binding activity of the purified VP6 protein as
determined by labeled ss-RNA EMSA. Different amounts of purified VP6 proteins of
BTV-11 were used for reactions with 50 ng of

32

P-labeled BTV-11 S3 minus sense

transcript for 5 min at room temperature before the reaction mixtures were analyzed by 4%
PAGE containing 6 M urea and autoradiography.
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Fig. 31. Single-stranded nucleic acid binding activity of the purified VP6 protein as
determined by small-transcript ss-RNA EMSA.

Different amounts of purified VP6

proteins of BTV-11 were used for reactions with 250 ng of 32P-labeled smaller transcript
(78 bases in length) for 5 min at room temperature before the reaction mixtures were
analyzed by 4% nondenaturing PAGE and autoradiography.
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Fig. 32. Single-stranded nucleic acid binding activity of the purified VP6 protein as
determined by ss-DNA EMSA. Different amounts of purified VP6 proteins of BTV-11
were used for reactions with 0.21J.g of M13 circular ss-DNA for 5 min at room temperature
before the reaction mixtures were analyzed by 0.8% agarose gel electrophoresis and
visualized by ethidium bromide staining. The retardation of the electrophoretic mobilities
of ss-DNA by purified VP6 was dosage dependent.
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Supershift of VP6-nucleic acid complex.

We conducted a supershift

analysis to further elucidate the relationship of these four antigenic epitopes recognized by
the MABs and the ss-nucleic acid binding domains.

Our assumption is if the binding

domains are adjacent to the antigenic epitopes, the binding of the monoclonal antibodies to
the VP6 protein will interfere with or inhibit the binding of VP6 to nucleic acids and no
mobility shift will be detected. If the binding domains and the antigenic determinants
recognized specifically by the four anti-VP6 monoclonal antibodies are distinct or distant
from each other, the antibodies will not interfere with the binding of nucleic acids by VP6.
We also predicted that the large molecular mass created when antibodies bind to VP6 would
cause a greater retardation, or "supershift," of the VP6-nucleic acid complex in EMSA. As
shown in Fig. 33, such a shift was evident in the four anti-VP6 monoclonal antibodies
(lanes 4 to 7), but not in the control ascites fluid (lane 8) and without the addition of VP6
(lanes 9 and 10).

These results suggested that the binding of the four antigenic

determinants on VP6 by these monoclonal antibodies did not disturb or interfere with the
ss-RNA binding activity of VP6. Thus the ss-nucleic acid binding sites and these four
antigenic epitopes are distinct.

Localization and mapping of ss-nucleic acid binding domains of VP6
by deletion mutant analysis.

To locate the ss-nucleic acid binding domains of VP6,

we constructed a series of C-terminal and internal deletion mutants of VP6.

We then

purified the heterologously expressed intact VP6 and truncated VP6 proteins to near
homogeneity (Fig. 25).

These purified VP6 proteins were used to locate and map the

domains responsible for ss-nucleic acid binding by EMSA. As shown in Fig. 34, the
specific binding of these truncated VP6 proteins to labeled ss-RNA transcript showed that
mutants #2 and 1 lost the nucleic acid binding activity (lanes 8 and 9). Mutants #34, 31,
and 36 had weaker binding activities (Fig. 34, lanes 6, 7 and 10).

Other C-terminal

mutants, #6, 20, and 4 (Fig. 7, lanes 3 to 5) and internal deletion mutants #37 and 38 (Fig.
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Cl6 Dl2 D34 Hl3 conl Hl3 cont

Fig. 33. Supershift of VP6-ss-RNA complex by monoclonal antibodies against
VP6 protein.

VP6 and yeast ss-RNA were mixed and incubated for 5 min at room

temperature. Purified monoclonal antibodies were added to the mixture and incubated for
another 1 hat room temperature. The reaction mixtures were analyzed by 0.8% agarose gel
electrophoresis and visualized by ethidium bromide staining. Molecular weight markers are
in lane 1. Supershift bands are present with monoclonal antibodies specific against VP6
(C16.1.1, 012.4.20, 034.5.7 and H13.1, respectively) as shown in lanes 4 to 7. Control
antibody does not show any supershift band in lane 8.

No gel retarded bands can be

detected without the addition of VP6 proteins (lanes 9 and 10).
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Fig. 34. ss-RNA binding activities of purified truncated VP6 proteins of BTV-11.
Purified truncated BTV VP6 proteins (4!lg each) and 78 base ss-transcripts (250 ng) were
used in EMSA under conditions similar to those described in Fig. 29. Note the absence of
mobility shift of labeled transcript when two of the smallest truncated VP6 proteins, #2 and
1 in lanes 8 and 9, respectively, were used for the binding assay.
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34, lanes 11 and 12), as well as intact VP6 (Fig. 34, lane 2) retained their binding
activities. Removal of the putative ATP/GTPbinding sites in the internal deletion mutants
(#37 and 38), did not affect the ss-RNA binding activities (Fig. 34, lanes 11 and 12).
Results were also similar with ss-DNA using these deletion mutants (data not shown).
The specific binding of truncated VP6 proteins to ss-RNA was further characterized
by a membrane overlay binding assay (MOBA) using

32

P-labeled positive and negative

sense BTV-11 S3 transcripts as probes (Fig. 35). Only C-terminal deletion mutants #6,
20, and 4 exhibited ss-RNA binding activities towards both positive and negative sense S3
gene transcripts (Fig. 35, lanes 2 to 4). However, C-terminal deletion mutants #34, 31, 2,
and 1, (Fig. 35, lanes 5 to 8) and internal deletion mutant #36 (Fig. 35, lane 9) did not
exhibit any binding activity, which slightly differed from the EMSA data. The difference
between these two methods in determining the ss-RNA binding activities of the truncated
VP6 proteins may be due to the possible lower sensitivity of detection of the membrane
overlay assay, or by conformational differences in the truncated VP6 proteins that failed to
regain their native state fully on the membrane after the renaturation steps.

When the

membrane overlay binding assays were repeated with no or insufficient renaturation steps,
no binding of the32P-labeled transcript probes was detected on any of the truncated VP6
proteins on the blots (data not shown). Thus specific nucleic acid binding depends on the
ability to regain the native state of VP6.

ss-RNA and ss-DNA binding activities of synthetic peptides of BTV
VP6.

To further confmn and identify the domains responsible for the ss-nucleic acid

binding activity, we used 11 VP6 sequence-specific synthetic peptides, each containing 10
to 15 residues, for both dot-blot analyses and EMSA. The locations and sequences of
these 11 peptides are shown in Table 3. The binding activities were determined using the
dot-blots containing two-fold dilutions of each peptide. Oligopeptides #70, 71, and 75
exhibited specific nucleic acid binding activities (Fig. 36). We have also carried out EMSA
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VP6 and the
deletion muiJlnt VP6
proteins (Jug)

#6 #20 #4 #34 #31 #2 #I #36

VP6

Probe : 32P-transcript
(positive sence of BllSJ gene)

#6 #20 #4 #34 #31 #2 #I #36
Probe : 32P-transcript
(negative sence of BllSJ gene)

Fig. 35. Membrane overlay binding assay of purified truncated VP6 proteins of
BTV -11. Purified truncated BTV VP6 proteins (3 J.lg each) were separated by 12% SDSPAGE. After renaturation in Western blotting buffer, the gels were blotted to nitrocellulose
membranes and the blots were incubated with

32

P-labeled BTV -11 S3 positive (A) or

negative (B) sense transcripts for 1 h at room temperature. Note that different ss-RNA
binding activities were observed as compared to the use of the same truncated VP6 proteins
in EMSA shown in Fig. 34.
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Binding of 32 P-ssRNA to sequence-specific synthetic
oligopeptides of VP6
Oligo-

peptide .....................
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Fig. 36. ss-RNA binding activities of eleven VP6-specific synthetic peptides by
dot-blot analyses. Two-fold diluted peptides were dot-blotted onto nitrocellulose
membranes and the blots were incubated with 32 P-labeled BTV-11 S3 transcripts positive
or negative sense for 1.5 h.
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Table 3. Summary of nucleic acid binding activity of VP6, its truncated deletion mutants
and sequence-specific oligopeptides

NH2

COOH

VP6

#6
#20
#4
#34
#31
#2
#1
#36

\C

Q.

;;.....
Q
~

E-

<
u

z;J
~

TEFLRLFDHL
TEFLRLFDHL

45k
43k

TEFLRLFDHL

46k

DVMRATAYFT*
ARESAVMLVS*
SEEPARIGIT
GG~QRKESH

DL~i<NGT
LQKELGi:SRE
- -KETKDADVDR

iii i i iii i i
#72 ( 35- 46) D-KENKTEPKEESK
VP6

+
+
+
+
+

TEFLRLFDHL

46k
43k
41k
37k
33k
30k
27k
15k
44k

TEF~RLFDHL

#37
#38

E-

MWoa
SDS-PAGE dsRNA

#74 ( 63- 78)
!:m-KEEGGKETKDADVDRR
#70 (181-193)
*•ERLRDLRRKEKSE
~ #71 (200-209)
*•ERGGRKQRKE
#73 (216-227)
Em-REGVEEEKTSEE
E- #75 (292-302)
*•KEVAREASKKK
~ A ( 10- 19)mt-KRSSEELKQR
Q. B (101-115)
mrDRGDGKVGGGGGDAD
c (142-153)
9-KYGTKIDVYRDE
D (252-262)
9-ERKNAPIGARE
E (313-323)
ml-DAKTEFLRLFD

9

Binding with
dsDNA
ssRNA

+
+
+
+
+

ssDNA

+
+
+
+
+
+

+
+
+
+
+
+

+ +
+ +
+ +

+
+
+
+.

+
+
+
+

+ +
+ +
+ +

+ +
+ +
+ +
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for these 11 peptides. As shown in Fig. 36 (A, B, and C), oligopeptides #70, 71, and 75
could bind andretard the electrophoretic mobilities of both ss-RNA extracted from yeast
(Fig. 37, lanes A-4, 5, and 9) and 32 P-labeled ss-RNA transcript (Fig. 38, lanes A-2, 3,
and 7). Similar results were obtained with ss-DNA (Fig. 39, lanes A-3, 4, and 8). The
other eight sequence-specific VP6 peptides did not exhibit any binding activity. These
results are similar to the ds-nucleic acid binding activity of VP6 (6).

The peptides #70

(residues #181 to 193) and #71 (residues #200 to 209) were adjacent to each other, but
peptide #75 (residues #292 to 302) was close to the C-terminus of the VP6 protein. Two
domains within the carboxyl portion of VP6 appeared to be responsible for ss-RNA and ssDNA binding activities, as well as for binding ds-nucleic acids (6).

The nucleic acid

binding activities of these 11 sequence-specific VP6 peptides are summarized in Table 3.

Concentration-dependent
synthetic peptides of VP6.

ss-nucleic

acid

binding

activities

of

As shown in Figs. 29 to 32, the binding of VP6 to ss-

nucleic acid was concentration-dependent.

We also determined whether the binding

activities of oligopeptides #70, 71, and 75 were also concentration-dependent. Various
amounts of these three synthetic peptides were incubated with 20 J..Lg of ss-RNA extracted
from yeast (Fig. 40), 250 ng of 32 P-labeled transcript (Fig. 41) and 0.4 J..Lg of M13 circular
ss-DNA (Fig. 42) in an EMSA.

The ss-nucleic acid binding activities of these three

oligopeptides were concentration-dependent.

Furthermore, the concentrations of

oligopeptide #71 and 75 required to affect the mobility of the ss-RNA appeared to be lower
than the concentration of oligopeptide #70 (Figs. 40 and 41). The effect of oligopeptide
#71 was also concentration-dependent (Fig. 42). Those observations are similar to results
when VP6 was incubated with ds-RNA and ds-DNA (6).

Competition using unlabeled nucleic acids. The specificity of the ss-RNA
binding activity of VP6 was further confmned by a competition experiment using unlabeled
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Fig. 37. ss-RNA binding activity of VP6-specific synthetic peptides. The binding
activities of eleven sequence-specific VP6 synthetic peptides toward ss-RNA extracted
from yeast were determined by EMSA. The experimental conditions used were similar to
those described for Fig. 29.
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Fig. 38. Small-transcript ss-RNA binding activity of VP6-specific synthetic
peptides. The binding activities of eleven sequence-specific VP6 synthetic peptides toward
32

P-labeled smaller transcript (78 bases in length) were determined by EMSA.

experimental conditions used were similar to those described for Fig. 31.

The
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Fig. 39. ss-DNA binding activity of VP6-specific synthetic peptides. The binding
activities of eleven sequence-specific VP6 synthetic peptides toward M13 circular ss-DNA
were determined by EMSA. The experimental conditions used were similar to those
described for Fig. 32.
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Fig. 40. EMSA of concentration-dependent ss-RNA binding activities of three VP6
sequence-specific oligopeptides. Various amounts of synthetic oligopeptides #70, 71 and
7 5 corresponding to the domains of VP6 were tested for their binding activities toward ssRNA extracted from yeast.
described for Fig. 29.

The experimental conditions used were identical to those
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EMSA of concentration-dependent small-transcript ss-RNA binding

activities of three VP6 sequence-specific oligopeptides.

Various amounts of synthetic

oligopeptides #70, 71 and 75 corresponding to the domains of VP6 were tested for their
binding activities toward

32

P-labeled smaller transcript (78 bases in length).

experimental conditions used were identical to those described for Fig. 31.

The
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-
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Fig. 42. EMSA of concentration-dependent ss-DNA binding activities of VP6
sequence-specific oligopeptide #71.

Various amounts of synthetic oligopeptides #71

corresponding to the domain of VP6 were tested for its binding activity toward M13 ssDNA. The experimental conditions used were identical to those described for Fig. 32.

yeast ss-RNA (Fig. 43). The shift in mobility of the

32
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P-labeled ss-RNA-VP6 complex

decreased as more unlabeled yeast ss-RNA was added (Fig. 43, lanes 3 to 10), probably
because the unlabeled ss-RNA competes for the binding of VP6 to

32

P-labeled ss-RNA,

suggesting the ss-RNA binding activity of VP6 was specific to the ss-RNA. To detennine
whether the ss-RNA binding domains were also shared by ds-RNA, ds-DNA, or ss-DNA,
we performed competition experiments between

32

P-labeled ss-RNA and nonlabeled ds-

RNA, ds-DNA, or ss-DNA in the presence of a constant amount of the VP6 protein. The
ss-RNA binding activity of VP6 competed with nonlabeled ds-RNA, ds-DNA and ss-DNA
(Figs. 44, 45, and 46), indicating that the ss-RNA binding domains of VP6 might be the
same as the domains responsible for ds-RNA, ds-DNA and ss-DNA binding activities.
However, the affinity of VP6 for ss-nucleic acids could be distinguished from the affinity
fords-nucleic acids.
DISCUSSION
The heterologously expressed intact and truncated VP6 proteins were purified to
near homogeneity (Fig. 25) and used to map the antigenic determinants of VP6 by MABs,
and to determine the potential ss- nucleic acid binding domains of VP6. The four anti-VP6
MABs recognized four different surface-accessible antigenic determinants in Western blots
(Figs. 26 and 27) and ELISA (Fig. 28). These four antigenic determinants were identified
and mapped between residues #1 to 77 (MAB D12.4.20), #77 to 325 (MAB C16.1.1),
#234 to 269 (MAB H13.1), and #284 to 325 (MAB D34.5.7). The size of the residues
recognized by MABs (C16.1.1, D12.4.20, and D34.5.7), suggests that at least three of
these four antigenic epitopes are conformational.
EMSA results using purified VP6 protein confrrmed that VP6 could bind to both ssRNA and ss-DNA in a concentration-dependent manner (Fig. 29). The ratio of VP6 to the
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1 2 3 4 5 6 7 8 9 10

78b transcript
32

++++++++++
VP6 (t.2ug) - + + + + + + + + +
P-ssRNA
(1 00113)

dsRNA (ug) -

----·

0.05 0.1 0.2 0.4 0.8 1.6 3.2 6.4

Fig. 43. Competition of the ss-RNA binding activities of VP6 protein by unlabeled
ss-RNA. The ss-RNA binding activity of VP6 was determined and confmned by the
addition of various amounts of unlabeled ss-RNA extracted from yeast.
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78b transcript

32p~~~~A
VP6

++++++++++
+++++++++

(t.2ug) -

dsDNA (ug) -

----·

0.05 0.1 0.2 0.4 0.8 1.6 3.2 6.4

Fig. 44. Competition of the ss-RNA binding activities of VP6 protein by unlabeled
ds-RNA.

The ss-RNA binding activity of VP6 was determined and confirmed by the

addition of various amounts of unlabeled BTV -11 ds-RNA.
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-

----·
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Fig. 45. Competition of the ss-RNA binding activities of VP6 protein by unlabeled
ds-DNA. The ss-RNA binding activity of VP6 was determined and confirmed by the
addition of various amounts of unlabeled CsCl-purified pCMVneo ds-DNA plasmid with
the BTV -11 S3 insert.
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1 2 3 4 5 6 7 8 9

+++++++++
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Fig. 46. Competition of the ss-RNA binding activities of VP6 protein by unlabeled
ss-DNA. The ss-RNA binding activity of VP6 was determined and confmned by the
addition of various amounts of unlabeled M13 circular ss-DNA.
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ss-transcripts required for complete binding was approximately 10: 1 (Fig. 30). The ratio
of VP6 to ss-DNA needed for a distinctive mobility shift was approximately 100:1 (Fig.
31). However, a ratio of VP6 to ds-RNA of 10:1 and a ratio of VP6 to ds-DNA of 30:1
are required to affect the migration of the two VP6-nucleic acid complexes (6). Thus VP6
has a similar affinity for ss- and ds-RNA but a slightly higher affinity for ds-DNA than for
ss-DNA.
These four MABs were further used to elucidate the relationships of these four
epitopes and ss-nucleic acid binding domains by supershift in EMSA (Fig. 33).

The

mobility of the VP6-ss-RNA complexes increased when the four MABs were added. This
indicates that these four antigenic determinants on VP6 (determined by these four MABs)
and the ss-nucleic acid binding domains were unique and distant from each other.
Results from the EMSA (Fig. 34) using purified intact and truncated VP6 proteins
showed that mutants #2 and 1 lost their ss- nucleic acid binding activity, and the binding
activities of mutants #34, 31, and 36 were weakened. Other C-terminal mutants, #6, 20,
and 4, internal deletion mutants #37 and 38 (removal of both ATP/GTP binding sites), as
well as the intact VP6, retained ss- and ds-RNA binding activities.

Thus the region

between residues #181 to 209 apparently was responsible for the ss-nucleic acid binding,
which is ATP/GTP independent. However, C-terminal deletion mutants #34, 31, 2, and 1,
and internal deletion mutant #36 did not exhibit the binding activity when

32

P-labeled

positive and negative sense BTV-11 S3 transcripts were used as probes in the membrane
overlay assay (Fig. 35). The difference in the ss-RNA binding activities of the truncated
VP6 proteins may reflect the lower sensitivity of detection of the membrane overlay assay
or the failure of truncated VP6 proteins to regain their native state during renaturation.
The domains responsible for the ss-nucleic acid binding activity were further
confrrmed and mapped using 11 VP6 sequence-specific synthetic oligopeptides for both
dot-blot analyses (Fig. 36) and EMSA (Fig. 37). The dot-blot analyses revealed that only
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oligopeptides #70, 71, and 75 exhibited ss-RNA binding activity.

These three

oligopeptides are rich in arginine and lysine and have high sequence conservation among
the five U.S. BTV serotypes. In EMSA, these three oligopeptides bound both ss-RNA
and ss-DNA.

Furthermore, the ss-nucleic acid binding activities of these three

oligopeptides were concentration-dependent (Figs. 40 to 42), similar to the binding activity
of VP6 protein (Figs. 29 to 32).
The specificity of ss-RNA binding activity for VP6 was also confmned by a
competition experiment using unlabeled ss-RNA as a competitor.
decrease in the mobility of the

The proportional

32

P-labeled ss-RNA-VP6 complex was evident as more

unlabeled ss-RNA was added (Fig. 45). This was evidence that VP6 specifically bound
the ss-nucleic acid. Furthermore, the results of competition experiments using nonlabeled
ds-RNA, ds-DNA, or ss-DNA, demonstrated that the ss-RNA binding domains of VP6
were also responsible fords-RNA and ds-DNA and ss-DNA binding (Figs. 43, 44, and
45), although there were slight differences in the affinities for ss- and ds-nucleic acid. As
shown in Fig. 34, C-terminal deletion mutant protein #31 and internal deletion mutant #36
weakly bound to ss-nucleic acid, but not to ds-nucleic acid (6).

The #70 site (residues

#181 to 193) was apparently responsible for ss-nucleic acid binding and #71 (residues
#200 to 209) was responsible for ds-nucleic acid binding of VP6.
These results complemented our previous report (6), and confmned that BTV VP6
could bind nucleic acid in ss-RNA, ss-DNA, ds-RNA, and ds-DNA, although it appeared
to have a slightly higher affinity for ss-nucleic acids than for ds-nucleic acids. Two major
domains were responsible for the nucleic acid binding activities of VP6. The domains
represented by oligopeptides #70 and 71 (residues #181 to 209) and #75 (residues #292 to
302) exhibit nucleic acid binding activities (Fig. 34, lanes 6, 7 and 10). The removal of the
#71 oligopeptide region in the deletion mutant #36 reduced binding to ds-RNA and
ds-DNA (6), suggesting that the #71 oligopeptide region is responsible for the ds-nucleic
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acid binding activity. The region might also function collaboratively with the domains of
#70 and 75. The #70 oligopeptide contributed more toss-nucleic acid binding activity than
to ds-nucleic acid binding activity. These results (Table 3) also indicate that both the basic
charges and conformation of these two domains/motifs are important in nucleic acid
binding, but it appears that the basic amino acids within these two domains are directly
involved and contributed to the binding of nucleic acids.
The biological functions of VP6 and its roles in the BTV infection are still
unknown. However, nucleic acid binding activities suggested that VP6 might be a helicase
that binds and unwinds the ds-RNA genome during the transcription. It is possible to test
inhibition of transcription activity in vitro using purified VP6 protein. VP6 may also serve
as an accessory protein for the RNA-dependent RNA polymerase of BTV, to facilitate the
binding of the polymerase to the ds-RNA genome in order to generate mRNA species and
to initiate viral replication. To investigate this possibility, the putative RNA-dependent
RNA polymerase of BTV must be obtained as purified protein.

The presence of the

potential methylase motif also suggests that VP6 might be a capping enzyme for the
methylation of BTV mRNA species.

We also believe that VP6 may contribute to

encapsidate the ds-RNA genome in the inner capsid of BTV. The presence of a nuclear
localization signal (NLS) near the amino terminus of VP6 might facilitate entry of VP6 into
the nucleus of the host and negatively affect the gene expression of the host by binding to
the host's cellular DNA (see "Expression and Characterization of BTV -11 VP6 Protein in
Mammalian Cells." p.146 to 158 in appendices). It is interesting to localize the expressed
VP6 and NLS-deletion mutant VP6 proteins in the mammalian cells following transfection
of the S3 and mutant S3 genes. We are currently investigating whether the differential
binding affmity to ss- and ds-nucleic acids by the VP6 protein can account for these
biological activities.
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CHAPTER IV
SUMMARY AND CONCLUSION
BTV is the causal agent of bluetongue disease (2, 4, 5, 8, 11), which has been
causing serious economic losses in the sheep industry (1, 3, 4). To prevent viral infection
and the spread of bluetongue disease, studies of the life cycle of BTV are crucial. Three
minor inner core proteins, VP1, 4, and 6, are prime candidates for the viral enzymes of
replication and transcription. Because ss- and ds-RNA and ds-DNA binding activities of
VP6 were reported (12), it has been suspected as a viral transcriptional enzyme such as
methyl transferase ( 10) and helicase (9). Since VP6 is one of these three minor inner core
proteins, and there might be only 30 to 40 molecules of VP6 per virion (6, 14), it is
necessary to obtain a large amount of purified native VP6 protein to study the biological
functions of this protein.
To obtain a sufficient amount of the VP6 protein of BTV, the S3 ds-RNA gene of
BTV -11 was reverse-transcribed to eDNA and cloned into a prokaryotic protein expression
system. The VP6 protein was expressed in a large amount as a glutathione-S-transferase
(GST)-VP6 fusion protein in E. coli, using the Glutathione Gene Fusion System
(Phannacia). Soluble VP6 protein was affmity-purified to near homogeneity from the
bacterial lysate with glutathione-conjugated Sepharose (G-beads), followed by thrombin
digestion (13). The amount of the purified VP6 protein recovered from this system was
dependent on the bacterial host strain, which harbored the pGEX-2T-B 11S3 plasmid.
Approximately 3 mg of purified VP6 protein per 1liter of bacterial culture (TOPP-2 strain)
could be obtained. The expressed GST-VP6 fusion protein in E. coli was highly sensitive
to an undetermined bacterial protease. The use of 25 to 27°C for growth of the host E. coli
and for induction with IPTG suppressed the expression of the protease and decreased
degradation of the GST-VP6 fusion protein. This bacterial protease was also inhibited by
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using 100 mM EDTA in the buffers for both lysis of the bacterial cells and extraction of the
GST-VP6 fusion protein with G-beads. A series of C-terminal (#6, 20, 4, 34, 31, 2, and
1) and internal deletion mutants (#36, 37, and 38) of S3 gene was also constructed. Each

deletion mutant S3 gene was cloned into the pGEX-2T vector. All of the truncated VP6
proteins were expressed as soluble protein in E. coli and purified to near homogeneity,
similar to the procedure for the intact VP6 protein.
The purified intact VP6 protein was used as an antigen to produce polyclonal and
monoclonal antibodies against VP6. According to the sequence information for the S3
genes of five U.S. serotypes (7), deduced amino acid sequences of VP6 were analyzed to
predict potential antigenic determinants, as well as nucleic acid binding sites, using Genetic
Computer Group computer software. Eleven sequence-specific oligopeptides, 10 to 16
amino acid residues in length (#70, 71, 72, 73, 74, 75, A, B, C, D, and E), were
synthesized chemically. Six of them (#70, 71, 72, 73, 74, and 75) were synthesized in the
multiple antigen peptide format and used to raise oligoclonal antibodies in rabbits. These
oligoclonal and monoclonal antibodies, the purified truncated VP6 proteins, and 11
sequence-specific oligopeptides were used to map and characterize the potential epitopes of
the VP6 protein using Western blot analysis and ELISA.
Four out of six oligoclonal antibodies, OABs #70, 71, 73, and 75, reacted well
with intact and truncated VP6 proteins on Western blots. These four regions could be
linear antigenic determinants or linear components of conformational epitopes. OABs #72
and 74 did not react with the denatured VP6 proteins on the blots. Purified native VP6
protein was immobilized on the wells of 96-well plates and used to detect reactivity with
these six OABs in ELISA. The result showed OABs #73, 74, and 7 5 reacted strongly with
native VP6. OABs #70 and 72 reacted moderately. OAB #71, which reacted strongly with
denatured VP6 on a Western blot, did not show reactivity with native VP6 in the ELISA.
The antigenic determinant recognized by OAB #71 may be linear and surface-inaccessible.
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The three antigenic determinants recognized by OABs #73, 74, and 75 are linear epitopes
on the surface of VP6. The determinant recognized by OAB #74 is a surface-accessible
and conformational epitope.
Four monospecific anti-VP6 MABs (C16.1.1, 012.4.20, 034.5.7, and H13.1) in
ascites fluids were used to map and characterize antigenic epitopes of VP6. Four MABs
were reacted with expressed and purified intact and truncated VP6 proteins on the Western
blots. Different reactivities of these four MABs towards these truncated VP6 proteins
indicated that the antigenic determinants recognized by MABs C16.1.1, 012.4.20,
034.5.7, and H13.1 are located at amino acid residues between #77 to 325, 1 to 77, 284 to
325, and 234 to 269, respectively. MABs 012.4.20, 034.5.7, and H13.1 also reacted
well with VP6 proteins of the five U.S. BTV on the blots. MAB C16.1.1 did not react
with these BTV VP6 proteins. The expressed and purified VP6 proteins in E. coli have an
additional13 amino acid residues at the N-terminus. These additional amino acid residues
might affect the conformation of the antigenic determinant recognized by MAB C 16.1.1.
The competitive immunodetection using 11 sequence-specific oligopeptides as competitors
indicated that none of these peptides showed any competition with these MABs.

This

means that the major components of antigenic determinants of four MABs were distinct
from the amino acid residues of 11 sequence-specific oligopeptides and also different from
the antigenic determinants of six oligoclonal antibodies. ELISA results with native VP6
protein suggested that at least three MABs (012.4.20, 034.5.7, and H13.1) are surfaceaccessible determinants.

The combined results of ELISA and Western blot analyses

indicated that these four antigenic determinants recognized by the MABs were distinct from
each other and also different from the six linear epitopes determined by OABs. Three of
them were likely to be surface-accessible type.
The purified intact VP6 protein in native form was used to confmn the nucleic acid
binding activity using electrophoretic mobility shift assay (EMSA). VP6 protein exhibited
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nucleic acid binding activities towards ds-RNA, ds-DNA, ss-RNA, and ss-DNA in a
concentration-dependent manner.

This unique VP6 protein still has binding activity

towards at least ds-RNA in the presence of 1.35 M NaCl, 8.0 M urea, or 4.8 M guanidine
HCl, but not in the presence of 0.1% SDS. Since nucleic acid binding activity of VP6 was
maintained after the conformational changes in the presence of high concentration of NaCl,
urea, and guanidine HCl but was destroyed by denaturation with anionic detergent (SDS),
extra negative charges obtained by SDS treatment might inhibit the interaction between VP6
and nucleic acid. Four purified MABs were further used to determine the relationship of
these antigenic determinants recognized by these MABs and ss-nucleic acid binding
domains, by supershift in EMSA. Supershift in the mobility of VP6-ss-RNA complexes
was evident for the four MABs, indicating that the ss-RNA binding sites and these four
antigenic epitopes were distinct. The specificity of the nucleic acid binding activity of VP6
was also confirmed by competition EMSA using nonlabeled nucleic acids. The competition
experiments between 32P-labeled ss-RNA and nonlabeled ds-RNA, ds-DNA, or ss-DNA in
the presence of a constant amount of VP6 protein revealed the possibility that VP6 can bind
these different forms of nucleic acids.
The ds-nucleic acid binding domains of VP6 were mapped using EMSA with the
purified truncated VP6 proteins. Results showed that the C-terminal deletion mutants #6,
20, 4, and 34, and internal deletion mutants #37 and 38, and intact VP6 all had ds-nucleic
acid binding activities, but C-terminal deletion mutants #31, 2, 1, and internal deletion
mutant #36 lost this binding activity. The amino acid sequence in the C-terminal region of
mutant #34 is rich in lysine and arginine and is highly conserved in the five U.S. BTV
serotypes.

The C-terminal region of mutant #34 corresponds to the region that was

removed in an internal deletion mutant #36, and to the region of sequence-specific
oligopeptide #71 (residues #200 to 209). This #71 region seems to be critical for the dsnucleic acid binding activity of the VP6 protein.
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The domains for the single-stranded nucleic acid binding activity of VP6 were also
mapped with EMSA and a membrane overlay binding assay (MOBA).

Based on the

EMSA results, the C-tenninal deletion mutants #6, 20, 4, and 34, and internal deletion
mutant #37 and 38, as well as intact VP6, all had ss-nucleic acid binding activity. Ctenninal deletion mutant #31 and internal deletion mutant #36 also bound ss-nucleic acid
weakly, but C-terminal deletion mutants #2 and 1 did not bind either ss-RNA and ss-DNA.
MOBA results using 32P-labeled S3 transcript as probes were slightly different from the
EMSA data. In MOBA, C-terminal deletion mutants #34, 31 and internal deletion mutant
#36 did not show ss-RNA binding activity, but in EMSA these truncated proteins showed
weak binding activity, indicating that regaining the native state of the protein is very
important for specific nucleic acid binding activity.
The domains responsible for binding activities towards ds- and ss-nucleic acids
were located near the center (residues #181 to 209) of amino acid sequence ofVP6, and the
affinity towards ds- and ss-nucleic acid by these two domains were distinct and different.
The deletion of two putative ATP/GTP binding sites in the internal deletion mutants #37
and 38 did not affect nucleic acid binding activity.
The 11 sequence-specific oligopeptides were also used to further identify the
domains responsible forthe nucleic acid binding activity of the VP6 protein. Three of the
oligopeptides (#70, 71, and 75) showed binding activities towards ds-RNA, ds-DNA, ssRN A and ss-DNA in a concentration dependent manner similar to the intact VP6 protein.
Combined results of the nucleic acid binding activity of the VP6 protein, using the
truncated VP6 proteins and oligopeptides were (i) three synthetic sequence-specific
oligopeptides (#70, 71 and 75) have binding activities towards both ds- and ss-nucleic
acids, suggesting that two domains that are located near the center (#70 and 71 regions:
residues #181 to 209) and near the C-terminus (#75 region: residues #292 to 302) could be
potential nucleic acid binding domains; (ii) the deletion of the #7 5 oligopeptide region did
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not affect nucleic acid binding activities of the truncated VP6 proteins; (iii) the deletion of
#71 region (residues #200 to 209) alone eliminated the binding activity towards ds-nucleic
acids; (iv) the deletion of both #70 and 71 regions is required for the elimination of ssnucleic acid binding activity of VP6 protein; (v) the domains consisting of #70 and 71
regions have a critical role for nucleic acid binding activities of VP6. However, the #71
region is important fords-nucleic acid binding activity, while the #70 region (residues #181
to 193) contributes more towards the ss-nucleic acid binding activity of VP6.
Through my research, the VP6 protein of BTV-11 was confnmed as a nucleic acid
binding protein towards ds-RNA, ds-DNA, ss-RNA, and ss-DNA, and the domains
responsible for these nucleic acid binding activities were mapped near the center (residues
#181 to 209) and near the C-tenninus (residues #292 to 302) of the VP6 protein. Ten
antigenic determinants of VP6 were mapped and characterized with oligoclonal and
monoclonal antibodies by Western blot analyses and ELISA. However, the enzymatic
activities and roles of VP6 protein in the life cycle of BTV are still unknown. The nucleic
acid binding activity confnmed by my research suggests that VP6 might be involved in the
encapsidation of the viral ds-RNA genome. The nonspecific binding activity towards dsDNA and the presence of a nuclear localization signal also suggest that VP6 might bind to
the host genome to inhibit transcription.

The potential presence of a capping enzyme

activity has been reported for inner core proteins (9, 10). VP6 has two putative ATP/GTP
binding sites (residues #100 to 107 and 114 to 121) with one amino acid mismatch
(residues #107 and 120), and 47% sequence similarity to the ATP-dependent RNA helicase
of Saccharomyces cerevisiae. VP6 might have an ATP-dependent helicase activity, which
binds and unwinds the ds-RNA genome during viral transcription in infected cells.
Mertens et al. ( 10) also hypothesized VP6 might be responsible for methyltransferase
activity. VP6 may serve as an accessory protein for the RNA-dependent RNA polymerase
of BTV, to enhance the binding of the polymerase to the ds-RNA genome for viral
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transcription and replication.

Many questions still remain to be answered by future

research on the VP6 protein of BTV.
During my research of the P6 protein, heterologously expressed intact and truncated
VP6 proteins, as well as sequence-specific peptides, played major roles in mapping and
characterization of nucleic acid binding domains and antigenic determinants of VP6. High
titer polyclonal and monoclonal antibodies were obtained using the purified intact VP6
protein as an antigen. Oligoclonal antibodies were also raised with the sequence-specific
oligopeptides and were used to map and characterize the antigenic determinants of VP6
protein.

Three of the sequence-specific oligopeptides (#70, 71, and 75) also were

concentration dependent for nucleic acid binding activities, similar to the full VP6 protein.
These observations suggested that synthetic oligopeptides could mimic major components
of antigenic determinants, and might be useful to screen nucleic acid binding activity of a
protein and to indicate sites responsible for the activity. Using similar approaches, the
relationships between structure and activity, such as a nucleic acid binding activity, of other
BTV proteins can be investigated.
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EXPRESSION AND CHARACTERIZATION OF BTV -11 VP6 PROTEIN IN
MAMMALIAN CELLS
ABSTRACT
Intact and truncated (#36) VP6 proteins of BTV serotype 11 were expressed in
BHK-21 cells by transfection with pCMVneo vectors containing the intact and internal
deleted S3 gene, respectively. The existence of the eDNA of S3 genes in the transfected
BHK-21 cells was confirmed by Southern blotting experiment using

32

P-labe1ed DNA

probe. The expressed VP6 proteins were analyzed by Western blots using polyclonal,
monoclonal and oligoclonal antibodies, and showed reactivities similar to VP6 protein in
purified BTV. The expression of the VP6 proteins in the BHK-21 cells continued for
approximately two months after the transfection.

However, the concentration of

expressed VP6 proteins in the cells was very low. The productivity and yield of the
infectious BTV in transfected BHK-21 cells were compared using plaque formation
assay. The result indicated that there was no significant difference in the production of
infectious BTV between BHK-21 cells transfected with pCMVneo and pCMVneoBTV11S3 gene.
INTRODUCTION
BHK-21 cells have been used as a host for BTV infection and amplification in
tissue-culture. Expression of VP6 protein of BTV in BHK-21 cells might affect the
synthesis of the BTV viral proteins. Expression of heterologous proteins in mammalian
cells results in appropriate processing and post-translational modifications such as
glycosylation, sulfation and acylation. These modifications might be important for
functions of the VP6 protein in the replication cycle of BTV. To initiate the study of
structure-function relationships of VP6, an experiment for eukaryotic expression of the
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VP6 protein in BHK-21 cells was designed using a cytomegalovirus-based vector,
pCMVneo. The human cytomegalovirus (HCMV) genome has been shown to contain a
strong transcriptional enhancer. This enhancer has little cell-type or species preference
and is several fold more active than the SV 40 enhancer (1). The pCMVneo plasmid
contains this transcriptional enhancer and two selectable markers as well as a cloning site.
Calcium phosphate transfection is one of commonly used methods to transfer
DNA into cells. The plasmid DNA containing the S3 genes were co-precipitated with
calcium phosphate and added to the BHK-21 cells. The DNA is taken up into phagocytic
vesicles of the cells (2). Transfection efficiencies of up to 1o- 3 have been obtained in a
variety of cell types. Using this method, stable transfection can be generated (7). The
intact and one of internal deletion mutants (#36) of S3 gene of BTV -11 were cloned into
the pCMVneo plasmid and positive clones were confirmed the right orientation of the
inserts against location of the CMV promoter in the plasmid.

Followed by the

transfection, the cells stably transformed with the DNA are isolated using a dominant
selectable marker which is included in the transfection vector such as a gene encoding
aminoglycoside phosphotransferase. This dominant selectable marker confers resistance
to 100-800 ug/ml of Oeneticin (0418) in the media (8). The intact and one of internal
deletion mutants (#36) of S3 gene of BTV -11 were cloned into the pCMVneo plasmid
and positive clones with the right orientation of the inserts were confirmed against the
location of the CMV promoter in the plasmid. Following the expansion of the 0418
resistant cells, insertion of the S3 genes in the host genome and expression of the VP6
proteins were confirmed by Southern blot and Western blot analyses. Furthermore,
productivity of infectious BTV with the transfected BHK-21 cells were investigated by
plaque formation assay.
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MATERIALS AND METHODS

Cells and virus. The method for purification of BTV was described previously
(5, 6, 9, 12) and in chapter II in this dissertation.

Construction of pCMVneo-B11S3 (pCMV -S3) and -81183 #36 (pCMV -36)
internal deletion mutant plasmids. The inserts intact and #36 internal deletion mutant
of BTV-11 S3 gene were obtained from pGEX2T-B11S3 and pGEX2T-B11S3#36
plasmids by digestion with BamH I. The digests were separated using agarose gel
electrophoresis, and the inserted DNA fragments were excised, followed by purification
using Geneclean Kit II (Bio 101). These insert DNAs were subcloned to the pCMVneo
plasmid at the Bgl II site which was compatible to the BamH I recognition site. The
transformants were screened by mini-prep method described (11) and in chapter ll in this
dissertation, and the orientation of the insert of positive clones were checked by Hind III
digestion of the purified plasmids. The pCMV-S3 and pCMV-36 plasmids as well as
pCMVneo plasmid were purified in a large scale for the subsequent transfection
experiment.

Transfection of the pCMVneo plasmids to BHK-21 cells and selection of the
transfected cells. The pCMV neo plasmids were transfected to BHK-21 cells using the
calcium phosphate method according to the method described in Molecular Cloning,
chapter 16 (10). Briefly, monolayered BHK-21 cells were trypsinized and resuspended in
lX MEM with 5% serum. After the number of the cells were counted, known numbers
of the cells (5 x 104 , 1 x lOs, and 2 x lOs cells) in 3 ml of the MEM medium were placed
in each well of the Multiwell™ (Becton Dickinson) plates, respectively. The BHK-21
cells in the wells were incubated for one day at 37°C in a C02 incubator. Then 110 JJ.l of
the purified plasmid solution (40 JJ.g/ml) in O.lX TE buffer was mixed with 125 JJ.l of 2X
HEPES-buffered saline (HBS), pH 7.05. Calcium phosphate-DNA co-precipitate was
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prepared by mixing 16.5 ~of 2M CaC1 2 slowly to 235

~1

of the DNA solution, followed

by incubation for additional 30 min at room temperature. The medium of the monolayer
of BHK-21 cells in MultiwellrM were removed, and the calcium phosphate-DNA coprecipitate suspension was added. After incubation for 15 min at room temperature, 3 ml
of medium (IX MEM with 5% serum) was added to each well, and the cells were
incubated for 1 day at 370C in a humidified 5% C02 incubator. After the medium was
removed, BHK-21 cells were incubated with the MEM medium containing 0.5 mg/ml of
Oeneticin (0418). The transfected cells, which contain the pCMVneo, pCMV-S3 or
pCMV-36 plasmids, can survive in the presence of 0418 antibiotics because of the
functional neo gene product amino glycosidase 3' phosphotransferase (APH).

Southern blot analysis of DNA from the transfected BHK-21 cells.

The

genome DNA of the BHK-21 cells were extracted by the benzyl chloride method (13).
The transfected BHK-21 cells were harvested, and pelleted by low speed centrifugation.
The cell pellets (about 0.1 gm wet weight) were resuspended in 0.5 ml of extraction
buffer (100 mM Tris-HCl, pH 9.0, 40 mM EDTA) containing 0.1 ml of 10% SDS and 0.3
ml of absolute benzyl chloride. The samples were vortexed and incubated at 50°C for 30
min with repeated vortexing at 5 min intervals. Approximately 3 ml of 3 M NaOAc, pH
5.0, was mixed with the sample and the tubes were kept on ice for 15 min. Following
centrifugation at 10,000 rpm for 10 min, the supernatant was mixed with same volume of
isopropanol. The DNAs were precipitated, washed with 70% ethanol and dried. The
purified genome DNAs were digested with EcoR I. The DNA fragments were separated
by 0.8% agarose gel electrophoresis. The DNA fragments in the gel were denatured with
0.5 M NaOH and 1.5 M NaCl, and the agarose gel was neutralized with 1.0 M Tris-HCl,
pH 7 .5, and 1.5 M NaCl. The DNA fragments were transferred to a nitrocellulose
membrane with lOX SSC overnight.

The blot was baked at 80°C for 2 h.

Prehybridization was performed in 6X SSC and 0.25% Carnation milk at 68°C overnight.
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The peMV -S3 probe was prepared by EcoR I digestion of the peMV -S3 plasmid. Mter
calf intestinal alkaline phosphatase treatment for the removal of 5' phosphates, the probe
was labeled at the 5' end by incubation with bacteriophage T4 polynucleotide kinase and
[)'-

32

P]ATP. The

32

P-labeled DNA probe was purified by phenol extraction and ethanol

precipitation. The 32 P-labeled probe was denatured by boiling for 5 min and chilled on
ice.

The blot was incubated at 68°e overnight with the denatured probe in the

prehybridization solution. The blot was washed with 2X SSe, 0.5% SDS at room
temperature twice (5 min and 15 min), with 0.1X SSe at 37°e and 68°e (1 h each) and
with 0.1X SSe at room temperature briefly. The blot was subjected to autoradiography.

Polyclonal, oligoclonal and monoclonal antibodies production.

The

production of polyclonal and oligoclonal antibodies against VP6 were described (3) and
in chapter II in this dissertation. MABs against VP6 were produced as described (4, 9,
12) and in chapter Ill using expressed and purified VP6 protein as antigen.

Analysis of the expressed VP6 proteins by SDS-PAGE, immunoprecipitation,
and immunodetection. The protocols used to analyze the expressed VP6 proteins by
SDS-PAGE, and preparation of immunoblots using nitrocellolose membrane were
described previously (3). To immunoprecipitate the expressed VP6 proteins in BHK-21
cells (BHK-VP6), the transfected cells in a flask (250 ml) were harvested, collected with
centrifugation at 2,000 rpm for 10 min, and washed with 50 mM Tris-Hel, pH 7.5, 150
mM Nael, 100 mM EDTA buffer (#1 buffer). The cells were resuspended in 0.5 ml of
the #1 buffer. The BHK-21 cell suspension was sonicated for 15 seconds four times with
40% of the output power using VirSonic Model 50 (VirTis), and centrifuged 10,000 rpm
for 5 min to obtain the supernatant that contains the expressed VP6 protein. The
supernatant was mixed with 10 J.tl of monoclonal antibody against VP6 (D34.5.7),
incubated at 4°e for 2 h. Mter 30 ,.U of 50% slurry of protein A-conjugated Sepharose in
1X PBS was added, the mixture was further incubated at 4°e for additional 1 h. The
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mixture was centrifuged at 10,000 rpm for 1 min, followed by extensive wash with #1
buffer. The washed Protein A-Sepharose with the VP6-antibody complex was analyzed
by 12% SDS-PAGE, blotted to nitrocellulose membrane followed by immunodetection as
described above.

Preparation of BTV seed stock from the transfected BHK-21 cells and plaque
formation assay. To prepare BTV seed stock for the comparison of BTV infectivity
produced in the transfected BHK-21 cells, 3 x 10 6 of the BHK-21 cells were added to a
roller bottle and incubated in 100 ml of 1X MEM containing 10% serum and 3 ml of 1M
N-2-hydroxyethylpiperazine-N' -3-propanesulfonic acid (HEPES), pH 7 .4, for 3 days at
37°C. The BHK-21 cells were then infected with BTV-17 at a multiplicity of infection
(MOl) of 1 (10 8 PFU/roller bottle) for 3 days at 37°C. Two roller bottles were prepared
for each type of BHK-21 transfected cells. After incubation, the infected BHK-21 cells
were harvested from roller bottles using the method for the purification of BTV described
(6) and in chapter II of this dissertation. The BTV -17 BHK-21 cell pellet from two roller
bottles was resuspended in 20 ml of 0.2 M Tris-HCl, pH 8.0, sonicated for 30 seconds
three times in the ice bath, centrifuged for 5 min at 2,000 rpm. The supernatant was used
as BTV -17 virus seed stock and stored at 4 °C until use. Similarly, these different BTV17 seed stocks were also prepared using the S3-transfected BHK-21 cells. The infectivity
of the BTV produced in the transfected BHK-21 cells was tested in triplicate by plaque
formation assay using Vero cells (monkey kidney cells) by the method described by
Hwang and Li (4). Vera cells in the wells of Multiwell™ were grown with 1X MEM
medium containing 5% serum at 37°C in a humidified 5% C02 incubator until cell
monolayers were formed. The monolayer cells were then infected with several dilutions
of BTV seed stocks produced with the transfected BHK-21 cell for 1 h at 37°C. After 1 h
incubation at 37°C, 4 ml of 10% Sephadex G-75 equilibrated with 1X MEM medium
containing 5% serum were added to each well as overlay. The infected cells were further
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incubated for 5 days at 37°C in a humidified 5% C02 incubator. The monolayer cells
were washed with 1X PBS, fixed with ethanol: 1X PBS (2: 1), and 95% ethanol, stained
with 0.5% crystal violet, and the plaques were counted to determine PFU/ml.
RESULTS

Construction of pCMVneo-BllS3 (pCMV-S3) and -B11S3 #36 (pCMV-36)
internal deletion mutant plasmids. When the S3 or #36 mutant gene was inserted in
the Bgl ll cloning site of the pCMVneo vector, the expected sizes of the EcoR I digested
plasmid fragments were 2.8, 2.7, 1.0 and 0.7 kb, respectively (Fig. 1A, lanes 7 and 8).
The expected sizes of the fragments of pCMVneo plasmid with EcoR I digestion were
3.5 and 2.7 kb, respectively (Fig. 1A, lane 6). The orientation of the inserts were also
checked by Hind III digestion of the plasmids (data not shown).

These results

demonstrated that S3 and #36 mutants were inserted in the right orientation and ready for
use in· transfection.

Transfection of BHK-21 cells by pCMVneo, pCMV-S3, and pCMV-36
plasmids. pCMVneo, pCMV-S3 and pCMV-36 plasmids were transfected to BHK-21
cell by the calcium phosphate method. The transfected BHK-21 cells were selected by
G418 in IX MEM containing 5% serum. The three different transfected BHK-21 cells
grew similarly as the untransfected BHK-21 cells. The transfected and selected BHK-21
cells were harvested. The host genome DNAs of BHK-21 cells were extracted using the
t

benzyl chloride method. The extracted and purified genome DNAs were digested with
EcoR I, and subjected to Southern blot analysis with 32 P-labeled EcoR !-digested pCMV-

S3 Dt,rA as a probe. As shown in Fig. lB (lanes 3, 4 and 5), the DNA from the three
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Fig. 47. Detection of the transfected pCMV-S3 genes in the BHK-21 cells by
Southern hybridization. The DNA samples from the transfected and 0418 selected
BHK-21 cells were EcoR I digested and transferred to a nitrocellulose membrane. The
blot was detected by 32P-labeled EcoR !-digested pCMV-S3 DNA probe. In panel A is
evident the separated DNA on 0.8% agarose gel stained with ethidium bromide. In panel
B is evident the autoradiogram of the blot detected with the 32P-labeled EcoR !-digested
pCMV-S3 probe. Lanes 1 and 10 are BstE II-digested A.DNA molecular weight markers.
Extracted DNAs from BHK-21 cells, which were not transfected, transfected with
pCMVneo, with pCMV -S3, and with pCMV -36, were shown in lanes 2 to 5. Lanes 6 to
8 are EcoR !-digested pCMVneo, pCMV -S3, and pCMV -36 plasmids, respectively.
Lane 9 also is the extracted DNA from BHK-21 cells with pCMV-S3 plasmid that lost
the expression of VP6 protein approximately two months posttransfection. Note that
there is no detectable pCMV-S3 DNA fragments in the BHK-21 cells that lost the VP6
expression.
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transfected BHK-21 samples showed specific binding with the

32

P-labeled pCMV-S3

probe, which also demonstrated similar band pattern to the plasmid (Fig. 1B, lanes 6, 7
and 8) that were used for the transfection. The expression of VP6 proteins in BHK-21
cells which were once transfected successfully with pCMV -S3, and with confirmed
expression of the VP6 protein was lost about 2 months after the transfection. The DNA
from these transfected BHK-21 cells (Fig. 1B, lane 9) as well as these from nontransfected BHK-21 cells (Fig. 1B, lane 2) did not hybridized with the

32

P-labeled

pCMV -S3 probe. These results are evidence that these pCMV vectors were successfully
transfected to the BHK-21 cells and the inserted genes that expressed the corresponding
VP6 proteins were stable in the transfected cell at least two months.
Expression of VP6 and the deletion mutant #36 proteins in the BHK-21 cells.
The control and 0418 selected BHK-21 cells were pelleted, treated with SDS-sample
buffer, and subjected to 12% SDS-PAGE followed by immunodetection using polyclonal
antibodies against VP6. As shown in Fig. 2, control (lane 1) and pCMVneo transfected
BHK-21 cell (lane 2) did not express VP6 protein. However, BHK-21 cells transfected
with pCMV -S3 (lane 3) and pCMV -36 (lane 4) showed expressed VP6 and the internal
deletion truncated protein, respectively.

However, SDS-PAGE gels stained with

Coomassie blue had no the bands corresponding to these expressed VP6 proteins (data
not shown). Thus concentration of the VP6 proteins in these transfected cells were very
low. The supernatant prepared from sonicated transfected BHK-21 cells were also used
for the immunoprecipitation of the VP6 proteins by monoclonal antibody D34.5.7 and
protein A-Sepharose. Expressed VP6 and truncated #36 proteins in the BHK-21 cells
could be seen clearly on the blot (Fig. 2, lanes 7 and 8), but the pCMVneo transfected
cells did not show any specific detection (Fig. 2, lane 6). These expressed VP6 protein
which reacted with monoclonal and oligoclonal antibodies against VP6, exhibited double
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12345678
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mutant protein

Fig. 48. Western blot analysis of expressed VP6 and the mutant #36 truncated
protein with internal deletion in BHK-21 cells. Transfected BHK-21 cells treated with
SDS-sample buffer were analyzed by 12% SDS-PAGE and then the gels were blotted to
nitrocellulose membranes, following by immunodetection with anti-VP6 polyclonal
antibody (1: 1,000 dilution), second anti-rabbit antibody conjugated with alkaline
phosphate, and the substrates (BCIP and NBT). Cellular lysate samples of control (lane
1) and pCMVneo transfected BHK-21 cells (lane 2) did not showed the expression of the
VP6 protein. BHK-21 cells transfected with pCMV-S3 (lane 3) and pCMV-36 (lane 4)
showed the expression of the VP6 and the internal deletion mutant protein in the BHK-21
lysates, respectively. Molecular mass markers are shown in lane 5. VP6 and the #36
mutant proteins in each transfected BHK-21 cells were immunoprecipitated using
monoclonal antibody D34.5.7 and protein A-Sepharose, and analyzed by western blot
with polyclonal antibody against VP6. The VP6 and #36 mutant proteins produced by
BHK-21 cells were immunoprecipitated and detected on the blot (lanes 7 and 8), but the
sample from pCMVneo transfected BHK-21 cells was not detected (lane 6).
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bands (VP6 and VP6a) on the immunoblots similar to the BTV VP6 protein (data not
shown), suggesting VP6 protein synthesized in the BHK-21 cells has similar antigenicity
to the BTV virion VP6. The S3 gene transfected with the pCMV vector transcribed 53specific mRNA that was translated similar to the S3 gene in the BTV infected cells.

Plaque formation assay of BTV produced with the transfected BHK-21 cells.
The transfected BHK-21 cells with pCMVneo and pCMV-S3 were used to produce BTV,
and the isolated BTVs were tested for the infectivity using Vero cells by plaque
formation assay. These transfected BHK-21 cells had confirmed the expression of BHKVP6 protein by immunodetection of Western blot. The result of this plaque formation
assay showed both transfected BHK-21 cells with pCMVneo and pCMV-S3 produced
infectious BTV with 4.18 x 106

± 2.37 x 106 , 4.26 x 106 ± 1.78 x 106 PFU/ml, respectively

(Table 4). This result suggested that the presence of additional expressed VP6 protein in
the BHK-21 cells did not affect the production of infectious BTV.

Table 4. Plaque formation assay for testing the infectivity of BTV produced in
transfected BHK-21 cells

Exp.

BTV produced in BHK-21 cells
transfected with pCMVneo
(PFU/ml)

BTV produced in BHK-21 cells
transfected with
pCMV -S3 (PFU/ml)

#1

3.25

X

106 ± 0.22 X 106

4.63

X

106 ± 0.23

X

106

#2

6.88

X

106 ± 0.47

X

106

2.32

X

106 ± 0.37

X

106

#3

2.42

X

106 ± 0.13

X

106

5.82 X 106 ± 0.46

X

106

Av.

4.18

X

106 ± 2.37

X

106

4.26

106 ± 1.78

X

106

X
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DISCUSSION
Intact S3 and S3 gene with internal deletion were cloned into pCMVneo plasmid.
The pCMVneo, pCMV-S3 and pcMV-36 plasmid were transfected to BHK-21 cells using
calcium phosphate method. The transfected BHK-21 cell were selected with G418 in the
medium by the presence of selectable marker gene on the pCMV neo plasmid. These
three kinds of transfected BHK-21 cells grew as well as non-transfected BHK-21 cells.
The presence of these S3 genes in the host genome DNA were detected by Southern blot
analysis. Intact and the internal deletion mutant of VP6 proteins of BTV-11 were
expressed in the BHK-21 cells for approximately two months and resulted in double
bands on the immunoblots similar to BTV VP6. The BHK-expressed VP6 also reacted
with antibodies similar to the VP6 and VP6a of BTV. Thus the expressed VP6 protein in
the BHK-21 cells had similar characteristics to BTV VP6. However, concentration of the
expressed VP6 proteins in the BHK-21 cells were very low. The transfected BHK-cells
with pCMVneo and pCMV-S3 were also used to produce BTV and the infectivity of the
resulted BTV were tested by plaque formation assay. There was no significant difference
between BTV isolated from transfected and non-transfected BHK-21 cells. Because of
low concentration of expressed VP6 protein in the cells, the effect of VP6 protein to the
host cells could not be evaluated effectively. To investigate nucleic acid binding activity
of the BHK expressed VP6 protein, purification of large amount of the VP6 protein is
critical. Immunoaffinity purification of the VP6 protein from these transfected BHK-21
cells is currently in progress.
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CONSERVATION OF THE SEGMENT 4 GENE SEQUENCE AND OF A LEUCINE
ZIPPER MOTIF IN VP4 AMONG FIVE US BLUETONGUE VIRUSES
I-Jen Huang, Emiko Hayama, Yoo-Jin Jeng, and Joseph K. -K. Li
Program in Molecular Biology and Department of Biology, Utah State University, Logan,
Utah 84322-5500
(Published in 1993: Virology 195, 772-779)
SUMMARY
Full-length eDNA copies of the segment 4 (Ml) genes of US Bluetongue viruses
serotype-2, -10, -11, -13, and -17 were selectively amplified using genomic doublestranded RNA segments from purified BTV virions as templates and a modified
polymerase chain reaction (Clamp-R). They were then cloned into pUC 19 plasmid and
both strands of several clones were sequenced. The length of all five segment 4 genes is
1981 nucleotides, which is 30 nucleotides shorter than that of the BTV serotype-1 0
reported by Y. Yu, A. Fukusho, and P. Roy (Nucleic Acids Res. 15, 7206 (1987)). The
5'- and 3' -noncoding regions of all five segment 4 genes are identical among all
serotypes. The plus sense strand of the BTV segment gene, which encodes the VP4
protein, possesses a single long open reading frame with an initiation codon (A TG) at
nucleotides 9-11 and a stop codon with a predicted molecular weight of about 75 KDa
and a pi of +7 to +7.9. A potential leucine zipper motif was detected near the carboxyl
terminus of the deduces VP4 amino acid sequence. The phylogenetic studies of cognate
genome segment 4 genes is consistent with the results of our previous phylogenetic
studies of cognate genome segments 5, 6, 8, 9, and 10. Serotype-10, -11,-13, and -17 are
closely related and serotype-2 is the most distantly related among the five US BTV
serotypes.
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SEQUENCE AND MOLECULAR PHYLOGETIC ANALYSES OF THE PUTATIVE
RNA-DIRECTED RNA POLYMERASE GENES OF
FNE US BLUETONGUE VIRUSES
1-Jen Huang*, Guang-Yuh Hwang@, Yi-Yuan Yang#, Emik:o Hayama*, and
Joseph K. -K. Li*
*Program in Molecular Biology and Department of Biology, Utah State University,
Logan, Utah 84322-5500, USA; @Department of Biology, Tunghai University,
Taichung, Taiwan, and #Department of Medical Technology,
Taipei Medical college, Taipei, Taiwan, ROC.
(Submitted in 1995: Virology)
SUMMARY
We determined the complete nucleotide sequences of the cognate L1 doublestranded RNA (ds-RNA) segments of bluetongue virus (BTV) serotypes 2, 11, 13, and
17, which encode the putative RNA-directed RNA polymerase VP1. Each cognate L1
segment contained 3,944 nucleotides. A single open reading frame (ORF) which could
encode the reported VP1 protein, 1,302 amino acids in size, began with an initiation
codon at nucleotides #12-14 and a termination codon at nucleotides #3,918-3,920. This
putative RNA-directed RNA polymerase (149 k.Da) was a basic protein with a predicted
net charge of +27 .5 at physiological pH. Analyses of the nucleotide and the deduced
amino acid sequences of the L1 cognate genes of the five US BTV serotypes indicated
that the most recently isolated BTV-2 serotype from Florida was more distantly related
than BTV-10, 11, 13, and 17, which were isolated primarily in western USA. The results
are consistent with our hypothesis that BTV-10, 11, 13, and 17 are derived from a single
and common gene pool, and that BTV-2 belongs to a second, distinct gene pool. These
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genetic distinctions also reflected well the known geographic distribution of the five US
BTV serotypes in North America. The deduced amino acid sequences of the cognate
VPl proteins contained seven highly conserved hydrophobic domains, three potential
"charged wheels" and leucine zippers, and other sequence motifs which were also found
in other known RNA polymerases.

164
CURRICULUM VITAE

Emiko Hayama
(May 1995)
EDUCATION:
Ph.D. candidate: 1991-present, Virology/Molecular Biology,
Utah State University, Logan, Utah 84322-5500, USA.
B.S.: 1977-1981, Department of Chemistry,
Faculty of Science, Tokyo Metropolitan University, Tokyo,
Japan.
MEMBERSHIP IN PROFESSIONAL SOCIETIES:
Member of Society of Chinese Bioscientists in America.
Member of American Society for Virology.
INDUSTRIAL EXPERIENCE:
1981-1987: Research staff scientist
1987-Present: Senior radiobiochemist, Head of pharmacodynamics division
Pharmacodynamic section, Institute of Whole Body Metabolism,
340-2, Nauchi, Shiroi, Inba, Chiba, Japan. Telephone: 0474-971089
TEACHING EXPERIENCE:
1993: Teaching assistant for Virology Laboratory.
1994: Teaching assistant for graduate Molecular Biology Laboratory.
AWARDS:
1)
2)

First place in student research paper competition on Scholars Day, May 17, 1994
at Utah State University, Logan, UT, USA.
Fourth place in student paper competition in the Annual American Society of
Microbiology Intermountain Branch Meeting, April 22, 1995 at Idaho State
University, Pocatello, ID, USA.

PUBLICATIONS:
1.

Hayama, et al. (1981). Microscale improvement of two-dimensional native PAGE
(polyacrylamide-gel electrophoresis) for analysis of human body fluids: plasma,
cerebrospinal fluids, and urine proteins. J. Biophysical Biochemical Society
(Japanese) 25, 161-166.

165
2.

3.

4.

Manabe, T., Hayama E., and Okuyama, T. (1982). Microscale multisample twodimensional electrophoresis of proteins in human serum, cerebrospinal fluid, and
urine. Clinical Chemistry 28, 824-827.
Hayama, et. al. (1988). Consideration of quantitative macro scale autoradiography,
Xenobiotic metabolism and disposition. Journal of Japanese Society of
Pharmacology 3, 181-189.
Hayama, E., Motoji, N., and Shigematsu, A. (1991). The kinetics and dynamics of
three kinds of radioactive methionine after i.v. administration in mice. European
Journal of Drug Metabolism and Pharmacokinetics 16, 287-297.

5.

Hayama, E., Motoji, N., Shigematsu. A., Kikuchi, H., Oohashi, T., and Yamazaki,
Y. (1992). Studies on the metabolic fate of MG 111 (1): Plasma concentration,
distribution, metabolism, excretion, transfer into fetus and milk after a single
intravenous administration of 1251-MG 111 to rats. Japanese Pharmacology and
Therapeutics 20, 3141-3167.

6.

Hayama, E., Motoji, N., Shigematsu. A., Kikuchi, H., Oohashi, T., and Yamazaki,
Y. (1992). Studies on the metabolic fate of MG 111 (2): Plasma concentration,
distribution, metabolism, excretion after repeated intravenous administration of 125 1MGlll to rats. Japanese Pharmacology and Therapeutics 20, 3169-3183.

7.

Hayama, E., Motoji, N., Shigematsu. A., Kikuchi, H., Oohashi, T., and Yamazaki,
Y. (1992). Studies on the metabolic fate of MG 111 (3): Plasma concentration,
excretion and distribution in blood cell after intravenous administration of 125 1MGlll to rabbits. Japanese Pharmacology and Therapeutics 20,3185-3190.

8.

Huang, I-J., Hayama, E., Jeong, Y.-J., and Li, J. K.-K. (1993). Conservation of the
segment 4 gene sequence and of a leucine zipper motif in VP4 among five US
bluetongue viruses. Virology 195, 772-779.

9.

Hayama, E., and Li, J. K.-K. (1994). Mapping and characterization of antigenic
epitopes and nucleic acid binding domains of the VP6 protein of bluetongue
viruses. Journal of Virology 68, 3604-3611.

10.

Motoji, N., Hayama, E., and Shigematsu, A. (1995). Studies on the quantitative
autoradiography. I. Radioluminography for quantitative autoradiography of 14C.
Bioi. Pharm. Bull. 18, 89-93.

11.

Motoji, N., Hayama, E., Shigematsu, A., Tazaki, S., Mori, N., and Miyahara, J.
(1995). Studies on the quantitative autoradiography. II. Radioluminography for
quantitative autoradiography of 3H. Bioi. Pharm. Bull. 18, 94-99.

12.

Huang, I-J, Hwang, G.-Y., Yang, Y.-Y., Hayama, E., and Li, J. K.-K. (1995).
Sequence and Molecular Phylogetic Analyses of The Putative RNA-directed RNA
polymerase Genes of Five US Bluetongue Viruses. (submitted)

13.

Hayama, E., and Li, J. K.-K. (1995). Identification of the conformational epitopes
and single-stranded nucleic acid binding sites of the VP6 protein of bluetongue
virus serotype 11. (submitted)

ABSTRACTS:
1.

Hayama, et al. (1982) Study on the binding of [1- 14C] monoiodoacetic acid with
protein in several organs or tissues. Pharmaceutical Society of Japan. Osaka, Japan.

166
2.

Hayama, et al. (1983) Localization of tritiated water in the brain of rabbit after i.v.
or suboccipital injection. Pharmaceutical Society of Japan.

3.

Hayama, et al. (1984) Host-parasite interaction in the liver lobes of C57BL/6 mice
after directly embedding B 16 melanoma into the lobe, assuming the incorporation
of [l- 14C] methionine, 35 S-methionine, and [U- 14 C] glucose 30 min after i.v.
injection. Pharmaceutical Society of Japan.

4.

Hayama, et al. (1985) Native 2 dimensional PAGE analysis of proteins
fractionated from the liver and serum of C57BL/6 mice after directly embedding
B 16 melanoma into the lobe, by use of autoradiographic identification.
Pharmaceutical Society of Japan.

5.

Hayama, et al. (1985) Host-tumor interaction after embedding of B16 melanoma
tumor into a liver lobe of C57BL mouse. 14th International Congress of
Biochemistry, Amsterdam, Netherlands.

6.

Hayama, et al. (1986) Native 2 dimensional PAGE analysis of serum proteins of
C57BL/6 mice after directly embedding B16 melanoma into the lobe, by use of
autoradiographic identification, Report II. Pharmaceutical Society of Japan.

7.

Hayama, et al. (1986) Metabolic fate of 3 kinds of radioactive methionines,
respectively, injected i.v. in C57BL/6 mice, (1) Separation and analysis of water
soluble proteins by native 2 dimensional PAGE. Pharmaceutical Society of Japan.

8.

Motoji, N., Hayama, E., and Shigematsu, A. (1986) Metabolic fate of 3 kinds of
radioactive methionines, respectively, injected i.v. in C57BL/6 mice, (2) Separation
and analysis of water soluble proteins in the pancreas of C57BL mice by SDSp AGE. Pharmaceutical Society of Japan.

9.

Hayama, et al. (1987) Metabolic fate of methionine, IV. Tissue distribution. 1st
Annual Xenobiotic Meeting of Metabolism and Disposition.

10.

Hayama, et al. (1987) Effect of administration routes on uptake of [U- 14C] glucose
into rat and rabbit brains. 107th Annual Meeting of Pharmaceutical Society of
Japan.

11.

Hayama, et al. (1988) Brain uptake index and brain autoradiographic
characterization. 2nd Meeting of ISSX International Society of Study for
Xenobiotics, Kobe, Japan.

12.

Hayama, et al. (1988) Effects of administration routes on glucose consumption in
rat brain. 3rd Annual Meeting of Xenobiotic Metabolism and Disposition.

13.

Hayama, et al. (1989) Studies on methionine dynamics, methionine metabolites
containing proteins after intravenous injection of 3 kinds of radioactive
methionines, revealed by native 2 dimensional PAGE. Second Meeting of
Xenobiotic Metabolism and Disposition.

14.

Hayama, et al. (1989) Effects of Xenobiotics on the brain, and metabolism of 14Cderivatives in the rat brain after long-term intravenous injection of [U- 14C] glucose.
Vth International Congress of Toxicology. Brighton, U.K.

15.

Huang, I-J., Hayama, E., Jeong, Y.-J., and Li, J. K.-K. (1992) Comparative
sequence analysis of segment 4 genes of five US bluetongue viruses. SCBA Fourth
International Conference at National University of Singapore, June 14-19, 1992,
Singapore.

167
16.

Li, J. K.-K., and Hayama, E. (1992) Location of two epitopes on VP6 of
bluetongue virus. Fourth International Symposium on Double-Stranded RNA
Viruses. December 12-16, 1992, at Scottsdale, Arizona, USA.

17.

Hwang, G.-Y., Li, J. K.-K., Yang, Y.-Y., Huang, 1-J., Hayama, E., and Chiou, J.-F.
(1992) Molecular phylogenetic analysis of bluetongue viruses using cognate gene
sequences representing half of the viral genome. Fourth International Symposium
on double-stranded RNA Viruses. December 12-16, 1992, at Scottsdale, Arizona,
USA.

18.

Hayama, E. (1993) Conservation of two antigenic epitopes within the multiple
forms of the cognate VP6 proteins among the five US bluetongue viruses. Viruses.
Scholars day, May 11, 1993 at Utah State University, Logan, UT, USA.

19.

Li, J. K.-K., and Hayama, E. (1993) Conservation of two antigenic epitopes within
the multiple forms of the cognate VP6 proteins among the five US bluetongue
viruses. SCBA Fifth International Conference. June 15-20,-1993 at University of
Maryland, Baltimore, USA.
.

20.

Huang, 1-J., Hayama, E., and Li, J. K.-K. (1993) Analysis of cognate gene
sequence, conserved leucine zipper motif and antigenic epitopes on VP4 protein of
five US bluetongue viruses. American Society of Virology-12th Annual Meeting.
July 10-14, 1993 at University of California, Davis, CA, USA.

21.

Hayama, E., and Li, J. K.-K. (1994) Expression, Purification and Characterization
of Antigenic Epitopes of the VP6 Protein of Bluetongue Virus 11. Intermountain
Branch American Society for Microbiology Meeting. April 30, 1994 at Brigham
Young University, Provo, UT, USA.

22.

Hayama, E., and Li, J. K.-K. (1994) Mapping and Characterization of Antigenic
Epitopes and the Nucleic Acid binding Domains of the VP6 Protein of Bluetongue
Viruses. Scholars day, May 17. 1994 at Utah State University, Logan, UT, USA.

23.

Hayama, E., and Li, J. K.-K. (1994) Mapping and characterization of the nucleic
acid binding domains of the VP6 protein of bluetongue virus 11. American Society
for Virology-13th Annual Meeting. July 9-13, 1994 at University of Wisconsin,
Madison, WI, USA.

24.

Li, J. K -K., Hayama, E., Huang, 1-J., Hwang, G.-Y., and Lin, H. (1994) New
paradigm in Bluetongue viruses: From molecular phylogeny to antigenic epitopes
and functional domains. First APSB International Symposium and Workshop.
August 15-18, 1994 at Singapore.

25.

Li, J. K.-K., and Hayama, E. (1994) Biospecific interaction of viral nucleic acid
with the cognate VP6 proteins of bluetongue viruses. First APSB International
Symposium and Workshop. August 15-18, 1994 at Singapore.

26.

Li, J. K.-K. Huang, 1-J., and Hayama, E. (1994) Role of RNA/protein interaction
in the packaging of the ten bluetongue virus double-stranded RNAs into the virion.
Third Asia-Pacific Congress of Medical Virology. October 23-28, 1994 at Beijing,
China.

27.

Li, J. K.-K., and Hayama, E. (1994) Characterization of the single-stranded
nucleic acid binding-domains and conformational epitopes of bluetongue virus
VP6. Fifth International Symposium on Double-stranded RNA-Viruses. March 1923, 1995 at Club Mediterrannee, Djerba, Tunisia.

168
28.

29.

Hayama, E., and Li, J. K.-K. (1995) Mapping of nucleic acid bindin~ domain~ of
the VP6 of bluetongue virus serotype 11. Intermountain Branch Amencan Soctety
for Microbiology Meeting. April22, 1995 at Idaho State University, ID, USA.
Hayama, E., Fillmore, C., and Li, J. K.-K. (1995) Identification of potential
nucleic acid binding sites of BTV VP1, the putative RNA-dependent RNA
polymerase, by sequence-specific oligopeptides. The 6th International SCBA
Symposium and Workshop. June 24-29, 1995 at Vancouver, Canada.

